Oxford Immunotec Global 10-K 5 Mar 15 2014 FY Annual report Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2014	Mar. 02, 2015	Jun. 30, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	Oxford Immunotec Global PLC
Document Type	10-K
Current Fiscal Year End Date	-19
Entity Common Stock, Shares Outstanding		22,509,772
Entity Public Float			$242,342,945
Amendment Flag	FALSE
Entity Central Index Key	1586049
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets
Cash and cash equivalents	$50,165	$76,494
Restricted cash	200	87
Accounts receivable, net	6,823	4,754
Inventory	6,425	5,450
Prepaid expenses and other	2,755	2,242
Total current assets	66,368	89,027
Restricted cash, non-current	192	362
Property and equipment, net	4,537	2,964
In-process research and development	2,399
Goodwill	50
Other intangible assets, net	273	331
Other assets	30	60
Total assets	73,849	92,744
Liabilities and shareholders’ equity
Accounts payable	2,368	2,310
Accrued liabilities	7,070	6,936
Deferred income	1,993	1,540
Current portion of loans payable	137	170
Taxes payable		177
Total current liabilities	11,568	11,133
Long-term portion of loans payable	454	563
Contingent purchase price consideration	1,218
Other liabilities		296
Total liabilities	13,240	11,992
Commitments and contingencies (Note 16)
Shareholders’ equity:
Ordinary shares, £0.006705 nominal value; 40,103,528 and 25,189,285 shares authorized at December 31, 2014 and 2013, respectively, 17,614,650 and 17,255,267, shares issued and outstanding at December 31, 2014 and 2013, respectively.	192	188
Additional paid-in capital	186,816	183,967
Accumulated deficit	-121,829	-99,655
Accumulated other comprehensive loss	-4,570	-3,748
Total shareholders’ equity	60,609	80,752
Total liabilities and shareholders’ equity	$73,849	$92,744

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals)	Dec. 31, 2014	Dec. 31, 2013	Nov. 21, 2013	Nov. 20, 2013
	GBP (£)	GBP (£)	USD ($)	USD ($)
Ordinary shares, nominal value (in Pounds per share)	£ 0.006705	£ 0.006705	$0.01	$0.00
Ordinary shares, shares authorized	40,103,528	25,189,285
Ordinary shares, shares issued	17,614,650	17,255,267
Ordinary shares, shares outstanding	17,614,650	17,255,267

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenue
Product	$25,407	$19,905	$9,080
Service	24,098	18,879	11,605
Total revenue	49,505	38,784	20,685
Cost of revenue
Product	11,225	8,475	4,329
Service	12,784	10,125	8,095
Total cost of revenue	24,009	18,600	12,424
Gross profit	25,496	20,184	8,261
Operating expenses:
Research and development	7,033	2,146	1,947
Sales and marketing	25,487	13,270	11,177
General and administrative	14,837	12,119	8,068
Total operating expenses	47,357	27,535	21,192
Loss from operations	-21,861	-7,351	-12,931
Other income (expense):
Interest expense, net	-52	-328	-1,477
Foreign exchange losses	-352	-423	-626
Other income (expense)	245	-470
Loss before income taxes	-22,020	-8,572	-15,034
Income tax expense (benefit)	154	92	-151
Net loss	($22,174)	($8,664)	($14,883)
Net loss per share attributable to ordinary shareholders—basic and diluted (in Dollars per share)	($1.28)	($2.26)	($8.44)
Weighted-average shares used to compute net loss attributable to ordinary shareholders—basic and diluted (in Shares)	17,310,148	3,830,837	1,763,728

Consolidated_Statements_of_Oth

Consolidated Statements of Other Comprehensive Loss (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Net loss	($22,174)	($8,664)	($14,883)
Other comprehensive (loss) income, net of taxes:
Foreign currency translation adjustment, net of taxes	-822	-126	345
Other comprehensive (loss) income, net of taxes	-822	-126	345
Total comprehensive loss	($22,996)	($8,790)	($14,538)

Consolidated_Statements_of_Sha

Consolidated Statements of Shareholders' Equity (USD $)	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Series F Preferred Stock [Member]	Series F Preferred Stock [Member]	Series G Preferred Stock [Member]	Series G Preferred Stock [Member]	Series G Preferred Stock [Member]	Issuance of F Preferred Ordinary Shares [Member]	Issuance of F Preferred Ordinary Shares [Member]	Issuance of F Preferred Ordinary Shares [Member]	Issuance of G Preferred Ordinary Shares [Member]	Issuance of G Preferred Ordinary Shares [Member]	Issuance of G Preferred Ordinary Shares [Member]	IPO [Member]	IPO [Member]	IPO [Member]	Common Stock [Member]	G Preferred Ordinary [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
In Thousands	Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member]	Preferred Stock [Member]	Issuance of F Preferred Ordinary Shares [Member]	Preferred Stock [Member]	Issuance of G Preferred Ordinary Shares [Member]	Preferred Stock [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]		G Preferred Ordinary [Member]	Additional Paid-in Capital [Member]		Common Stock [Member]	Additional Paid-in Capital [Member]
					Preferred Stock [Member]		Preferred Stock [Member]
Balance at Dec. 31, 2011	$2	$1	$5	$33		$25													$14		$85,221	($76,108)	($3,967)	$5,226
Issuance of stock					1		16			1	1,314	1,316		16,685	16,701				9		-9
Interest on convertible notes settled with G preferred ordinary shares																					90			90
Share-based compensation expense																					79			79
Other comprehensive income (loss)																							345	345
Net loss																						-14,883		-14,883
Subscription of G preferred ordinary shares																				8,075				8,075
Balance at Dec. 31, 2012	2	1	5	33		26		16											24	8,075	103,380	-90,991	-3,622	16,949
Exercise of share options																			1		21			22
Issuance of stock							11						-8,075	11,006	2,942	67	63,812	63,879
Ordinary shares issued upon conversion of note payable and accrued interest																			2		5,608			5,610
Conversion of preferred ordinary shares in connection with initial public offering	-2	-1	-5	-33		-26		-27											94
Share-based compensation expense																					140			140
Other comprehensive income (loss)																							-126	-126
Net loss																						-8,664		-8,664
Balance at Dec. 31, 2013																			188		183,967	-99,655	-3,748	80,752
Exercise of share options																			1		13			14
Issuance of shares from option plan																			3		-3
Issuance of shares from exercise of warrants																					318			318
Share-based compensation expense																					2,521			2,521
Other comprehensive income (loss)																							-822	-822
Net loss																						-22,174		-22,174
Balance at Dec. 31, 2014																			$192		$186,816	($121,829)	($4,570)	$60,609

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net loss	($22,174,000)	($8,664,000)	($14,883,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,742,000	1,101,000	801,000
Share-based compensation expense	2,521,000	140,000	79,000
Loss on change in fair value of warrants	22,000	279,000
Loss on change in fair value of derivative instrument		561,000
(Gain) loss on disposal of property and equipment		-1,000	71,000
Noncash interest expense			1,425,000
Changes in operating assets and liabilities:
Accounts receivable, net	-2,311,000	637,000	-3,103,000
Inventory	-1,214,000	-2,808,000	-1,045,000
Prepaid expenses and other	-594,000	-881,000	-333,000
Accounts payable	-109,000	483,000	196,000
Accrued liabilities	768,000	2,947,000	1,608,000
Deferred income	572,000	587,000	814,000
Net cash used in operating activities	-20,777,000	-5,619,000	-14,370,000
Cash flows from investing activities
Purchases of property and equipment	-3,014,000	-1,809,000	-1,482,000
Purchases of intangible assets	-354,000	-205,000	-79,000
Cash paid for acquisition, net of cash acquired	-1,716,000
Proceeds on sales of property and equipment		22,000
Change in restricted cash	57,000	225,000	-315,000
Net cash used in investing activities	-5,027,000	-1,767,000	-1,876,000
Cash flows from financing activities
Proceeds from revolving line of credit			1,500,000
Proceeds from convertible note		4,842,000	4,000,000
Proceeds received in advance of share issuance			8,075,000
Proceeds from issuance of ordinary shares		63,879,000
Proceeds from issuance of preferred ordinary shares		2,942,000	12,701,000
Proceeds from exercise of share options	14,000	22,000	1,000
Proceeds from term loan		6,582,000
Payments on loan	-165,000	-6,068,000	-60,000
Payments on revolving line of credit		-1,500,000
Net cash (used in) provided by financing activities	-151,000	70,699,000	26,217,000
Effect of exchange rate changes on cash and cash equivalents	-374,000	603,000	273,000
Net (decrease) increase in cash and cash equivalents, excluding restricted cash	-26,329,000	63,916,000	10,244,000
Cash and cash equivalents at beginning of year	76,494,000	12,578,000	2,334,000
Cash and cash equivalents at end of year	50,165,000	76,494,000	12,578,000
Supplemental disclosures
Cash paid for interest	50,000	240,000	81,000
Cash paid (received) for taxes	115,000	70,000	-281,000
Noncash investing and financing activities
Interest on convertible notes settled with G preferred ordinary shares			90,000
Warrants liability reclassified to additional paid-in capital upon exercise of warrants	318,000
Fair value of warrant issued with convertible note		296,000
Series F Preferred Stock [Member]
Noncash investing and financing activities
F preferred ordinary shares issued with convertible notes			1,316,000
Series G Preferred Stock [Member]
Noncash investing and financing activities
Convertible notes converted into ordinary shares			4,000,000
Common Stock [Member]
Noncash investing and financing activities
Convertible notes converted into ordinary shares		$5,049,000

Note_1_Description_of_Business

Note 1 - Description of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	1. Description of business and significant accounting policies
	Description of business
	Oxford Immunotec Global PLC (the “Company”), is a global, commercial-stage diagnostics company focused on developing and commercializing proprietary tests for the management of immune-regulated conditions. The Company’s proprietary T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. Substantially all of the Company’s revenue is currently derived from the sale of its T-SPOT.TB test, which is sold in two formats: an in vitro diagnostic kit format (allowing customers to perform the test at their own institutions), and a service format (in which the Company performs the test on samples sent by customers to the Company’s own laboratory facilities). The Company markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan. The Company markets its test through distributors in other parts of the world.
	On July 31, 2014, the Company acquired substantially all of the assets of Boulder Diagnostics, Inc. (“Boulder”), a privately owned company developing immunology-based assays for autoimmune and inflammatory conditions/diseases. The assets acquired primarily relate to assays for Lyme disease and gout and an assay to inform decisions regarding biologic therapies.
	Reorganization, reverse share split and conversion, and initial public offering
	On October 2, 2013, the Company completed a scheme of arrangement under the laws of England and Wales, or the Scheme of Arrangement, which was approved by the High Court of Justice in England and Wales. All holders of ordinary shares, preferred ordinary shares, options and warrants exchanged their interests in Oxford Immunotec Limited for identical interests in Oxford Immunotec Global PLC. As a result of this exchange, Oxford Immunotec Global PLC became the parent company of Oxford Immunotec Limited.
	In November 2013, prior to closing of the Company’s initial public offering, the Company undertook a 1 for 6.705 reverse share split of its outstanding ordinary shares, which resulted in a proportional decrease in the number of ordinary shares outstanding as well as appropriate adjustments to outstanding A ordinary shares, preferred ordinary shares, warrants and options. After the reverse share split and immediately prior to the Company’s IPO, all outstanding preferred ordinary shares converted into ordinary shares. The nominal value of the ordinary shares was adjusted from £0.001 to £0.006705 per share. Prior period share and per share amounts have been adjusted to reflect the reverse share split.
	On November 21, 2013, the registration statement for the Company’s initial public offering, or IPO, was declared effective by the Securities and Exchange Commission. The Company sold 6,164,000 ordinary shares, at an initial public offering price of $12.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 804,000 additional ordinary shares. Net proceeds from the IPO were $63.9 million, after deducting underwriting discounts and commissions and offering expenses.
	Initial public offering (IPO) costs
	Incremental costs incurred that were directly attributable to the November 2013 offering of securities were deferred and deducted from the related proceeds of the offering, and the net amount recorded as contributed shareholders’ equity in the period when such shares were issued. As at December 31, 2013, the Company had deducted $10.1 million from the related net proceeds of the offering for underwriting and other fees. Other costs incurred in the offering of $1.9 million (which were principally related to audit and accounting expenses) in the year ended December 31, 2013, were expensed as incurred and included in general and administrative expenses.
	Basis of presentation, accounting principles and principles of consolidation
	The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP), and include the financial statements of Oxford Immunotec Global PLC, a company incorporated in England and Wales and its wholly-owned subsidiaries, collectively referred to as the Company. The financial statements include the results of Oxford Immunotec Limited and its consolidated subsidiaries for the period prior to the completion of the Scheme of Arrangement, as well as the results of Oxford Immunotec Global PLC and its consolidated subsidiaries for the period after completion of the Scheme of Arrangement. All intercompany accounts and transactions have been eliminated upon consolidation.
	Segment reporting
	The Company operates in one operating segment. The Company’s chief operating decision maker (the CODM), its chief executive officer, manages the Company’s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews separate revenue information for the Company’s product and service offerings and for each country, while all other financial information is on a combined basis. While the Company’s principal operations and decision-making functions are located in both the United States and United Kingdom, the CODM makes decisions on a global basis. Accordingly, the Company has determined that it operates in a single reporting segment.
	Use of estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and that affect the reported amounts of revenue and expenditures during the reporting periods. Actual results could differ from those estimates and assumptions used.
	Foreign currency translation
	The functional currency for Oxford Immunotec Global PLC is the U.S. Dollar. The functional currency for the Company’s operating subsidiaries are the Pound Sterling for Oxford Immunotec Limited, the U.S. Dollar for Oxford Immunotec Inc., the Yen for Oxford Immunotec K.K., and the Euro for Boulder Diagnostics Europe GmbH. Revenue and expenses of foreign operations are translated into U.S. Dollars at the average rates of exchange during the year. Assets and liabilities of foreign operations are translated into U.S. Dollars at year-end rates. The Company reflects resulting translation gains or losses in accumulated other comprehensive income, which is a component of shareholders’ equity. The Company does not record tax provisions or benefits for the net changes in foreign currency translation adjustments, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries.
	Realized and unrealized foreign currency transaction gains or losses, arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies, are included in “Other income (expense)” in the consolidated statements of operations.
	Concentration of risks
	The Company derives product revenue from the sale of its T-SPOT.TB diagnostic test kits and related accessories to a broad range of customers including: hospitals, public health departments, commercial testing laboratories, importers and distributors. Importers and distributors sell to third parties including end-user customers in specific territories.
	In the year ended December 31, 2014, the Company had two product customers that represented more than 10% of the Company’s annual revenue. The Company’s Chinese distributor, Shanghai Fosun Long March Medical Science Co. Ltd., or Fosun, represented 17% of annual revenue and the Company’s Japanese importer, Riken Genesis Co., Ltd. represented 14% of annual revenue. The loss of either of these product customers could have a material impact on the Company’s operating results.
	In October 2013, the Company issued a convertible promissory note in the amount of $5.0 million to Fosun Industrial Co., Ltd., (the Fosun Note). The Fosun Note paid interest at 8% per annum. In connection with the Company’s IPO in November 2013, the Fosun Note and interest of approximately $50,000 converted into 467,551 of the Company’s ordinary shares at a price per share which reflected a 10% discount to the IPO offering price of $12.00 per share. Upon conversion of the Fosun Note to ordinary shares, the derivative liability terminated. In connection with the IPO the Company marked the embedded derivative to market and recorded a $561,000 loss on the change in the fair value of the instrument.
	Cash and cash equivalents
	The Company maintains its available cash balances in cash, money market funds primarily invested in U.S. government securities, and bank savings accounts in the United States, United Kingdom, Germany, and Japan. The Company maintains deposits in government insured financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
	Restricted cash
	As of December 31, 2014 and 2013, U.S. bank balances totaling $312,000 and $399,000, respectively, were pledged as security for the Company’s U.S. office and laboratory space operating leases.
	As of December 31, 2014 and 2013, the Company had restricted cash of less than $100,000 pledged as collateral for procurement cards issued by a U.S. commercial bank.
	Accounts receivable
	Accounts receivable are primarily amounts due from hospitals, public health departments, commercial testing laboratories, distributors and universities in addition to third party payors such as commercial insurance companies and government programs (Medicare and Medicaid).
	Accounts receivable are reported net of an allowance for uncollectible accounts. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management’s analysis of current and past due accounts, collection experience and other relevant information. The Company’s provision for uncollectible accounts is recorded as a bad debt expense and included in general and administrative expenses. Although the Company believes amounts provided are adequate, the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided.
	Inventory
	Inventory consists of finished goods and raw materials. The Company does not maintain work in progress balances as the nature of the manufacturing process does not allow for test kits to be left in a partially manufactured state. Inventory is removed at cost. Inventory is stated at the lower of cost or market. Cost is determined by the actual cost of components by batch plus estimated labor and overhead costs per unit. Market value is based on an estimated selling price less any costs expected to be incurred to completion and sale. The Company reviews the components of its inventory on a periodic basis for excess, obsolete or impaired inventory, and records a reserve for the identified items. At December 31, 2014 and 2013, the Company determined no inventory reserve was required.
	Property and equipment
	Property and equipment are stated at cost. Property and equipment includes specialized shipping containers provided to customers, in the United States, for transporting samples to its laboratory for testing. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease.
	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three to ten years for laboratory equipment, office equipment and furniture and fixtures and three years for software and specialized shipping containers.
	Revenue recognition
	The Company derives product revenue from the sale of its T-SPOT.TB diagnostic test kits and related accessories to a broad range of customers including hospitals, public health departments, commercial testing laboratories, importers and distributors.
	Product revenue is generally paid directly by the customer and is recognized on an accrual basis when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) the product has been shipped or delivered in accordance with the shipping terms of the arrangement; (3) the price is fixed or determinable and known at time of shipment; and (4) collectability is reasonably assured.
	For products sold in Japan, the price currently only becomes determinable upon the wholesaler dispatching kits to satisfy a firm order from its customer and, as a result, this is when the Company recognizes revenue for such sales.
	No product return rights are extended to customers of the Company.
	The Company derives service revenue from its diagnostic laboratories in the United States and in the United Kingdom where the Company performs its T-SPOT.TB test on samples sent by customers to its laboratory facilities.
	Service revenue in the United Kingdom and revenue from direct bill customers in the United States are recognized on an accrual basis when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) when the diagnostic result has been delivered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. This service revenue is referred to as “direct-bill” sales because the Company receives payment directly from the ordering entity.
	In the United States, the Company also generates revenue from payments that are received from a variety of third-party payors, including government programs (Medicare and Medicaid) and commercial insurance companies, each with different billing requirements. Revenue from tests paid by third-party payors is recognized on an accrual basis based on the Company’s historical collection experience.
	Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations.
	Cost of revenue: cost of product and cost of service
	Cost of product revenue consists primarily of costs incurred in the production process, including costs of raw materials and components, assembly labor and overhead, quality costs, royalties paid under licensing agreements, the U.S. medical device excise tax and packaging and delivery costs.
	Cost of service revenue consists primarily of costs incurred in the operation of the Company’s diagnostic laboratories including labor and overhead, kit costs, quality costs, consumables used in the testing process and packaging and delivery costs.
	Shipping and handling
	The Company does not normally bill its service customers for shipping and handling charges. Charges relating to inbound and outbound freight costs are incurred by the Company and recorded within cost of service.
	The Company generally bills product customers for shipping and handling and records the customer payments as product revenue. The associated costs are recorded as cost of product sold.
	Impairment of long-lived assets
	The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may be impaired, and assesses their recoverability based upon anticipated future cash flows. If changes in circumstances lead the Company to believe that any of its long-lived assets may be impaired, the Company will (a) evaluate the extent to which the remaining book value of the asset is recoverable by comparing the future undiscounted cash flows estimated to be associated with the asset to the asset’s carrying amount and (b) write-down the carrying amount to market value to the extent necessary. There has been no impairment of long-lived assets to date.
	Business combinations
	For acquisitions meeting the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically determined by using either estimates of replacement costs or discounted cash flow valuation methods.
	When determining the fair value of tangible assets acquired, the Company estimates the cost using the most appropriate valuation method with assistance from independent third party specialists. When determining the fair value of intangible assets acquired, the Company uses judgment to estimate the applicable discount rate, growth rates and the timing and amount of future cash flows. The fair value of assets acquired and liabilities assumed is typically determined by management using the assistance of independent third party specialists. The assumptions used in calculating the fair value of tangible and intangible assets represent the Company’s best estimates. If factors change and the Company were to use different assumptions, valuations of tangible and intangible assets and the resulting goodwill balance related to the business combination could be materially different.
	The terms of the purchase agreement with Boulder included contingent purchase price consideration consisting of future potential milestone payments totaling up to $6.1 million at any time on or prior to July 31, 2024. The milestone payments consist of completion of studies related to acquired technologies, development of diagnostic test kits, patient enrollment in an Institutional Review Board approved study, issuance of patents, and approvals or clearances by the U.S. Food and Drug Administration. The fair value of future potential milestone payments was determined based upon a probability weighted analysis of expected future milestone payments to be made to the seller. This analysis includes significant management judgments related to the probabilities of success assigned to the milestones and to the discount rate utilized in the calculations.
	Goodwill and indefinite-lived intangible assets
	Goodwill
	Goodwill is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate that all, or a portion, of the carrying value of the reporting unit may no longer be recoverable, using the two-step impairment review. Under this method, the Company compares the fair value of the goodwill to its carrying value. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine if goodwill is impaired. An impairment loss, if any, is measured as the excess of the carrying value of goodwill over the fair value of goodwill. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads it to determine that it is more likely than not (that is, a likelihood of more than 50%) that goodwill is impaired. If the Company chooses to first assess qualitative factors and it is determined that it is not more likely than not goodwill is impaired, it is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which it may choose to do in some periods but not in others.
	Indefinite-lived intangible assets
	The Company’s indefinite-lived intangible assets consist of acquired in-process research and development (“IPR&D”), related to the Company’s business combination with Boulder, which were recorded at fair value on the acquisition date. IPR&D intangible assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. If the fair value of the intangible asset is less than the carrying amount, the Company performs a quantitative test to determine the fair value. The impairment loss, if any, is measured as the excess of the carrying value of the intangible asset over its fair value. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads it to determine that it is more likely than not (that is, a likelihood of more than 50%) that its indefinite-lived intangible asset is impaired. If the Company chooses to first assess qualitative factors and it is determined that it is not more likely than not its indefinite-lived intangible asset is impaired, it is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which it may choose to do in some periods but not in others.
	The determinations as to whether, and, if so, the extent to which, acquired IPR&D become impaired are highly judgmental and based on significant assumptions regarding the projected future financial condition and operating results, changes in the manner of the use and development of the acquired assets, the Company’s overall business strategy, and regulatory, market and economic environment and trends.
	Definite-lived intangible assets
Intangible assets include technology licenses which are capitalized and amortized over estimated useful lives (generally in the range of five to ten years) using the straight-line method. On an ongoing basis, the Company assesses the recoverability of its intangible assets by determining its ability to generate undiscounted future cash flows sufficient to recover the unamortized balances over the remaining useful lives. Intangible assets determined to be unrecoverable are expensed in the period in which the determination is made.
Derivative financial instruments
The Company does not use derivative instruments to hedge exposures to cash flow, market, interest rate or foreign currency risks.
The Company reviews the terms of the shares and warrants it issues and its convertible promissory notes to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as other income or expense. When equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.
Fair value of financial instruments
The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of December 31, 2014 and 2013, the Company’s financial instruments consist of cash and cash equivalents, accounts receivable, prepaid expenses, and other accounts payable, accrued liabilities, and loans payable. As of December 31, 2013, the Company’s financial instruments also included ordinary share warrants. See Note 2 “Fair value measurement,” to the consolidated financial statements for further information on the fair value of the Company’s financial instruments.
Research and development expenses
Research and development expenses include all costs associated with the development of the Company’s T-SPOT technology platform and potential future products including new diagnostic tests that utilize the T-SPOT technology platform and are charged to expense as incurred. In addition, with the acquisition of Boulder in the third quarter of 2014, the Company has expanded its research efforts to include assays for Lyme disease and gout and an assay to inform decisions regarding biologic therapies. Research and development expenses include direct costs and an allocation of indirect costs, including amortization, depreciation, rent, supplies, insurance, and repairs and maintenance.
Restructuring Charges
For restructuring plans meeting all of the applicable criteria of ASC 420, Exit or Disposal Cost Obligations, one time termination benefits will be recognized if no future service is required of former employees. Costs associated with the termination of contracts before the end of their term, where costs will continue to be incurred without economic benefit to the entity, will be recognized as liabilities and initially measured at fair value on the date the contract is terminated or when the Company is no longer using the rights conveyed under the contract. Liabilities for other costs associated with restructuring plans will be recognized in the period they were incurred (generally upon receipt of the goods or services). Restructuring charges will be included in the appropriate operating expense category in the Company’s consolidated statements of operations.
Share-based compensation
The Company accounts for share-based compensation arrangements with employees, officers and directors by recognizing compensation expense based on the grant date fair value of share-based transactions in the consolidated financial statements.
Share-based compensation for options is based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for share options and recognized as expense on a straight-line basis over the requisite service period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility, expected term and forfeiture rates. The expected volatility rates are estimated based on the actual volatility of comparable public companies over a historical period equal in length to the expected term. The expected terms represent the average time that options are expected to be outstanding based on the midpoint between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying cash dividends in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards.
Beginning in 2014, certain employees have been granted restricted shares. There were no issuances of restricted shares in 2013 or 2012. The fair value of restricted shares is calculated based on the closing sale price of the Company’s ordinary shares on the date of issuance. No restricted shares have vested.
The cumulative expense recognized for share-based transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit for a period represents the movement in cumulative expense recognized as of the beginning and end of that period. No expense is recognized for awards that do not ultimately vest.
Where the terms of an equity award are modified, the minimum expense recognized is the expense as if the terms had not been modified if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based compensation, or is otherwise beneficial to the employee as measured at the date of modification.
Where a share-based compensation award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.
Upon exercise, share options are redeemed for newly issued ordinary shares.
Income taxes
The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and its financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.
The Company adheres to the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken, or expected to be taken, in a tax return. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company does not have any accrued interest or penalties associated with any unrecognized tax positions for the years ended December 31, 2014 and 2013.
Ordinary share warrant policy
Warrants to purchase the Company’s ordinary shares are classified as equity unless otherwise required. Warrants issued with a down round provision, whereby the exercise price would be adjusted downward in the event that additional ordinary shares of the Company or securities exercisable, convertible or exchangeable for the Company’s ordinary shares are issued at a price less than the exercise price, are recorded as a liability and marked to market each reporting period until they are exercised, expire or are otherwise extinguished. Changes in the liability during each reporting period are recorded in other income (expense). The Company has not issued warrants since its IPO in November 2013.
Basic and diluted net loss per ordinary share
Earnings or net loss attributable to ordinary shareholders for the period, after deduction of preferred ordinary share preferences, are allocated between the ordinary shareholders and preferred ordinary shareholders based on their respective rights to receive dividends. Basic and diluted net loss per ordinary share is determined by dividing net loss applicable to ordinary shareholders by the weighted-average number of ordinary shares outstanding during the period. As the Company reports net losses, outstanding share options, warrants and preferred ordinary shares, have not been included in the calculation of diluted net loss attributable to ordinary shareholders per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. Since the Company’s participating preferred ordinary shares were not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per share, no allocation was made to preferred ordinary shares if a net loss existed. Prior period share and per share amounts have been adjusted to reflect the reverse share split.
Recent accounting pronouncements
In May 2014, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers, or ASU 2014-09 which converges the FASB and the International Accounting Standards Board standard on revenue recognition. Under ASU 2014-09, a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The guidance allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. The Company is currently evaluating ASU 2014-09 and has not yet determined how it may impact the Company’s financial position or results of operations and related disclosures.
In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern, or ASU 2014-15. ASU 2014-15 will be effective for fiscal years and interim periods beginning after December 15, 2016 and early application is permitted. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity’s ability to continue as a going concern within one year of the date that the financial statements are issued. The Company does not expect that the application of ASU 2014-15 will have an impact on the presentation of its results of operations, financial position or disclosures.
In November 2014, the FASB issued ASU 2014-16, Derivatives and Hedging, or ASU 2014-16. The objective of ASU 2014-16 is to eliminate the existing diversity in practice in accounting for hybrid financial instruments issued in the form of a share. A hybrid financial instrument consists of a “host contract” into which one or more derivative terms have been embedded. ASU 2014-16 requires an entity to consider the terms and features of the entire financial instrument, including the embedded derivative features, in order to determine whether the nature of the host contract is more akin to debt or to equity. ASU 2014-16 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. A reporting entity should apply ASU 2014-16 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the annual period of adoption. Retrospective application is permitted to all relevant prior periods. The Company does not expect that the application of ASU 2014-16 will have an impact on the presentation of its results of operations, financial position or disclosures.
In November 2014, the FASB issued ASU 2014-17, Business Combinations, or ASU 2014-17. ASU 2014-17 provides guidance that allows all acquired entities to choose to apply pushdown accounting in their separate financial statements when an acquirer obtains control of them. The new guidance is effective immediately. The Company does not expect that the application of ASU 2014-17 will have an impact on the presentation of its results of operations, financial position or disclosures.
In January 2015, the FASB issued ASU 2015-01, Income Statement—Extraordinary and Unusual Items, or ASU 2015-01. ASU 2015-01 eliminates from GAAP the concept of extraordinary items. However, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring. The amendments in ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not expect that the application of ASU 2015-01 will have an impact on the presentation of its results of operations, financial position or disclosures.

Note_2_Fair_Value_Measurement

Note 2 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	2. Fair value measurement
	As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level I—Observable inputs such as quoted prices in active markets for identical assets or liabilities.
	Level II—Observable inputs, other than Level I prices, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level III—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amount of certain of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable, and accrued liabilities approximate fair value due to their short maturities.
	Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability.
	The following tables present information about the balances of liabilities measured at fair value on a recurring basis and indicates the fair value hierarchy of the valuation techniques it utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates, and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. The Company did not have any financial assets measured at fair value on a recurring basis.
					Fair value measurements at December 31, 2014 using
	(in thousands)	December 31,			Quoted prices in		Significant		Significant
		2014			active markets		other		unobservable
					for		observable		inputs
					identical assets		inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Contingent purchase price consideration	$	1,218		$	—	$	—	$	1,218
	Total	$	1,218		$	—	$	—	$	1,218
					Fair value measurements at December 31, 2013 using
	(in thousands)	December 31,			Quoted prices in		Significant		Significant
		2013			active markets		other		unobservable
					for		observable		inputs
					identical assets		inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Ordinary share warrants	$	296		$	—	$	—	$	296
	Total	$	296		$	—	$	—	$	296
	In May 2013, the Company entered into a loan and security agreement with Square 1 Bank that provided for an initial borrowing of $6.0 million and, subject to the achievement of certain revenue milestones, the ability to borrow an additional $1.0 million in January 2014. The Company also received access to a $5.0 million revolving line of credit. The Company concurrently issued a warrant to purchase up to 15,791 ordinary shares of the Company at an exercise price of $0.80 per share. Due to the lack of market quotes relating to the Company’s ordinary share warrants, the fair value of the warrants was determined using the Black-Scholes model, which is based on Level 3 inputs. In December 2013, following the Company’s IPO, the Company repaid the loan in full and canceled the line of credit.
	In April 2014, Square 1 Bank converted its warrant and received 15,148 ordinary shares of the Company, in accordance with a formula stated in the warrant agreement. Prior to the warrant conversion, the fair value of the warrant was adjusted to its fair value at the date of exercise of $318,000, with the loss on change in fair value recorded in the statement of operations. The liability for the warrant on conversion was then reclassified to additional paid-in capital.
	On July 31, 2014, the Company acquired substantially all of the assets of Boulder, a privately owned company developing immunology-based assays for autoimmune and inflammatory conditions/diseases. The terms of the purchase agreement included contingent purchase price consideration consisting of future potential milestone payments totaling up to $6.1 million at any time on or prior to July 31, 2024. The milestone payments consist of completion of studies related to acquired technologies, development of diagnostic test kits, patient enrollment in an Institutional Review Board approved study, issuance of patents, and approvals or clearances by the U.S. Food and Drug Administration. The fair value of future potential milestone payments was determined based upon a probability weighted analysis of expected future milestone payments to be made to the seller, which are considered as Level 3 inputs.
	The following tables provide a summary of changes in the fair value of the Company's Level 3 financial liabilities for the years ended December 31:
	(in thousands)	2014
	Balance – beginning	$	296
	Change in fair value of warrant liability		22
	Reclassification of liability to additional paid-in capital upon exercise of warrants		(318	)
	Contingent purchase price consideration		1,247
	Change in fair value of contingent purchase price consideration		72
	Foreign currency adjustment		(101	)
	Balance – ending	$	1,218
	(in thousands)	2013
	Balance – beginning	$	—
	Initial fair value of warrants at issuance in May 2013		17
	Change in fair value of warrant liability		279
	Reclassification of liability to additional paid-in capital upon exercise of warrants		—
	Balance – ending	$	296
	The change in fair value of the warrant liability is included general and administrative expense in the Company’s condensed consolidated statements of operations and the change in fair value of contingent purchase price consideration is included in research and development expense.

Note_3_Accounts_Receivable

Note 3 - Accounts Receivable	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Financing Receivables [Text Block]	3. Accounts receivable
	Accounts receivable, net, consisted of the following as of:
		December 31,
	(in thousands)	2014			2013
	Accounts receivable	$	6,937		$	4,919
	Less allowance for uncollectible accounts receivable		(114	)		(165	)
	Accounts receivable, net	$	6,823		$	4,754
	Activity for the allowance for uncollectible accounts receivable is as follows:
		December 31,
	(in thousands)	2014			2013			2012
	Balance at beginning of period	$	(165	)	$	(144	)	$	(200	)
	Provision for bad debt expense		—			(124	)		—
	Write-off, net of recoveries		51			103			56
	Balance at end of period	$	(114	)	$	(165	)	$	(144	)

Note_4_Inventory

Note 4 - Inventory	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	4. Inventory
	Inventory consisted of the following as of:
		December 31,
	(in thousands)	2014		2013
	Raw materials	$	3,605	$	2,866
	Finished goods		2,820		2,584
	Inventory, net	$	6,425	$	5,450

Note_5_Property_and_Equipment_

Note 5 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property and equipment, net
	Property and equipment, net consists of the following as of:
		December 31,
	(in thousands)	2014			2013
	Laboratory equipment	$	2,815		$	2,072
	Leasehold improvements		2,869			2,029
	Office equipment, furniture and fixtures		2,603			2,025
	Software		1,065			692
	Specialized shipping containers		1,088			294
	Property and equipment		10,440			7,112
	Less accumulated depreciation		(5,903	)		(4,148	)
	Property and equipment, net	$	4,537		$	2,964
	For the years ended December 31, 2014, 2013, and 2012, the Company recorded depreciation expense of $1.8 million, $1.0 million, and $0.7 million, respectively. Depreciation expense includes amortization of capital leases.
	Depreciable lives range from three to ten years for laboratory equipment, office equipment, leasehold improvements, and furniture and fixtures and three years for software and specialized shipping containers.
	For the years ended December 31, 2014 and 2013, there were no material capital leases, disposals or retirements.

Note_6_Intangible_Assets

Note 6 - Intangible Assets	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Intangible Assets Disclosure [Text Block]	6. Intangible assets
	The Company’s definite-lived intangible assets include in-licensed intellectual property, principally technology licenses. During the year ended December 31, 2012, the Company entered into a new license agreement under which it capitalized $0.1 million. During the year ended December 31, 2013, the Company capitalized a $0.2 million fee related to the assignment of certain patents to it by Isis Innovation Limited (Isis) in November 2013. The licenses are being amortized over the estimated remaining useful lives of the underlying license agreements, which range from 3 to 9 years. The weighted-average useful life of the license agreements is 8.3 years. For the years ended December 31, 2014, 2013, and 2012, the Company recorded amortization expense of $43,000, $43,000, and $30,000, respectively. Amortization expense is estimated at $41,000 for 2015, $41,000 for 2016, $41,000 for 2017, $26,000 for 2018, and $25,000 for 2019.
	Definite-lived intangible assets, originally denominated in GBP, as of December 31, 2014 and 2013 consist of the following:
		December 31,
	(in thousands)	2014			2013
	Gross carrying value	$	828		$	878
	Accumulated amortization		(555	)		(547	)
	Other intangible assets, net	$	273		$	331
	On July 31, 2014, the Company acquired substantially all of the assets of Boulder, a privately owned company developing immunology-based assays for autoimmune and inflammatory conditions/diseases. In conjunction with the acquisition, the Company acquired $2.6 million of indefinite-lived IPR&D and recorded $55,000 of goodwill. The following table sets forth the changes in the carrying amount of goodwill for the five-month period subsequent to the acquisition, ended December 31, 2014 (in thousands):
	Goodwill from Boulder acquisition	$	55
	Foreign currency adjustment		(5	)
	Balance at end of period	$	50
	For more information on the Boulder acquisition, see Note 18 “Acquisition activity”.

Note_7_Accrued_Liabilities

Note 7 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7. Accrued liabilities
	Accrued liabilities consist of the following as of:
		December 31,
	(in thousands)	2014		2013
	Employee related expenses	$	3,348	$	2,766
	Royalties		2,458		2,064
	Professional services		323		99
	Rent		196		366
	Inventory		88		293
	Accrued initial public offering costs		—		845
	Other accrued liabilities		657		503
	Total accrued liabilities	$	7,070	$	6,936

Note_8_Borrowings

Note 8 - Borrowings	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	8. Borrowings
	In February 2012 the Company entered into a secured credit facility with a commercial bank that provided for borrowings of up to $3.0 million originally through February 2013 and extended through May 2013. In February 2012 the Company borrowed $1.5 million under the credit facility. Interest accrued daily on the outstanding balance at the prime rate plus 1.5% per annum, with a minimum of the Daily Adjusting LIBOR rate plus 2.5% per annum. The credit facility was secured by substantially all assets of the Company. The total amount outstanding on the facility as of December 31, 2012 was $1.5 million. The loan was re-paid in full on May 24, 2013. The Company had no borrowings in 2014.
	In connection with this credit facility, the Company issued a warrant to purchase up to 3,682 ordinary shares of the Company at an exercise price of $0.06705 per ordinary share. The warrant became exercisable immediately upon entering the secured credit facility and was to expire in February 2019. The fair value of the warrant was $3,000 at the date of grant and was determined by applying the Black-Scholes option pricing model, using the following assumptions:
		Fair value		Valuation technique	Assumption	Input
		at date				range/
		of grant				value
	Warrant liability ($ in thousands)	$	3	Black-Scholes	Expected volatility		37.6	%
				option pricing model
					Estimated fair value of ordinary share	$	0.14
					Exercise price	$	0.01
					Expected term (in years)	3
					Dividend yield		0	%
					Risk-free interest rate		0.37	%
	The warrant was exercised in March 2014, and the Company issued 3,682 ordinary shares and received proceeds of $257.74.
	In February 2012, the Company entered into an unsecured convertible note agreement with existing investors allowing the Company to borrow a total of $4.0 million. The Company issued unsecured convertible notes (the 2012 Notes) in two separate tranches of $3.0 million and $1.0 million in March 2012 and April 2012, respectively. The 2012 Notes matured four months after funding. The 2012 Notes bore interest at 10% per annum and interest was payable upon redemption or conversion.
	Concurrently with the issuance of each tranche of the 2012 Notes the Company was obligated to pay the holders of the 2012 Notes a facility fee, payable in F preferred units, which consisted of one F preferred ordinary share and one-third of an ordinary share per unit. The number of F Preferred Units issued was equal to 50% of the nominal amount of each tranche of the 2012 Notes, divided by $1.622, with no fractional shares issued. 137,922 F preferred ordinary shares and 45,973 ordinary shares were issued in connection with the March 2012 tranche and 45,974 F preferred ordinary shares and 15,324 ordinary shares were issued in connection with the April 2012 tranche. The fair value of the F Preferred Units on the dates of issuance totaled approximately $2.0 million. The proceeds from the 2012 Notes were allocated to the 2012 Notes and F Preferred Units based on the relative fair value of each on the issuance dates. The F Preferred Units were recorded as a discount to the 2012 Notes carrying value of $1.3 million to be amortized to interest expense over the term of the 2012 Notes.
	The 2012 Notes were (1) automatically convertible upon the consummation of a qualifying equity fundraising into the class of shares to be issued to investors participating in the fundraising at the price per share at which such shares would be offered, (2) automatically convertible upon the consummation of a non-qualifying equity fundraising into either the class of shares to be issued to investors participating in the fundraising at the price per share at which such shares would be offered or F Preferred Units at a price of $10.876 per unit, as elected by holders of at least 65% of the nominal amount of outstanding notes, or (3) convertible into F Preferred Units at a price of $10.876 per unit, at the option of the holders of at least 65% of the nominal amount of outstanding notes upon the consummation of a debt fundraising.
	The feature which required automatic conversion upon a qualifying or non-qualifying equity fundraising was a redemption feature that met the definition of an embedded derivative and required bifurcation from the 2012 Notes. The derivative was recorded as a liability with a corresponding discount to the 2012 Notes’ carrying value at its fair value of $0.1 million. The discount was amortized to interest expense over the term of the 2012 Notes.
	The feature which provided for the optional conversion upon the consummation of a debt fundraising represented a beneficial conversion feature. Because the beneficial conversion feature was contingent upon a future debt fundraising that was not certain to occur, the beneficial conversion feature was not recognized in the Company’s financial statements until the contingency was resolved. In June 2012, the Company closed the first tranche of the G preferred ordinary share financing round. Both tranches of the 2012 Notes were converted into a total of 350,923 shares of G preferred ordinary shares. In a conversion of a convertible bond pursuant to the original conversion terms the debt was settled in exchange for equity and no gain or loss was recognized on conversion. At the conversion date the discount on the borrowing was fully amortized. The redemption feature was adjusted to its fair value of zero upon conversion and the liability was reduced to this amount with an offsetting adjustment to interest expense.
	In May 2013, the Company entered a loan and security agreement with a commercial bank that provided for an initial borrowing of $6.0 million and, subject to the achievement of certain revenue milestones, the ability to borrow an additional $1.0 million in January 2014. The Company also received access to a $5.0 million revolving line of credit. The Company concurrently issued a warrant to purchase up to 15,791 ordinary shares of the Company at an exercise price of $0.80 per share. The loan was secured by substantially all assets of the Company. Interest accrued daily on the outstanding balance at the prime rate plus 2.75%, with a minimum 6.0% per annum. The loan agreement contained certain restrictions on the Company, including restrictions on additional indebtedness, dispositions, dividend payments and future loans. The term loan was repaid and the credit facility was cancelled in December 2013, following the Company’s IPO. In addition, the bank released the Company from the security interest in its assets. In conjunction with the termination of the term loan and the credit facility, $142,000 of deferred loan costs were expensed. The warrant became exercisable upon issuance and was to expire in May 2023. The proceeds from the loan were first allocated to the warrant based upon the estimated fair value as of the issuance date, with the residual proceeds allocated to the term loan. This warrant was issued with a down-round provision whereby the exercise price would be adjusted downward in the event that additional ordinary shares or securities exercisable, convertible or exchangeable for the Company’s existing ordinary shares were issued at a price less than the exercise price. Therefore, the fair value of this warrant was recorded as a liability in the consolidated balance sheet and was to be marked to market at each reporting period end until it was exercised or expired or was otherwise extinguished.
	The fair value of the warrant was recorded as a liability upon issuance with a corresponding discount on the borrowing of $17,000 to be amortized to interest expense over the term of the loan. The estimated fair value of the warrants at December 31, 2013 was $296,000. The change in the estimated fair value of the warrants during the period ended December 31, 2013 was recorded as a component of other income (expense) in the consolidated statement of operations. The fair value was derived by applying the following assumptions:
		Fair value		Valuation technique	Assumption	Input
		at December 31,				range/
		2013				value
	Warrant liability ($ in thousands)	$	296	Black-Scholes option	Expected volatility		48.6	%
				pricing model
					Estimated fair value of ordinary share	$	19.38
					Exercise price	$	0.8
					Expected term (in years)	9.4
					Dividend yield		0	%
					Risk-free interest rate		2.64	%
	In April 2014, the holder of the warrant to purchase 15,791 of the Company’s ordinary shares elected to exercise the warrant through a cashless conversion, as defined in the warrant agreement. As a result, in April 2014 the Company issued 15,148 ordinary shares in full settlement of the warrant.
	In June 2013, in conjunction with the lease for approximately 14,500 square feet of office space in Marlborough, Massachusetts, the Company received a payment of $581,640 from the landlord, representing approximately 80% of the cost to build-out the facility. In accordance with Financial Accounting Standards Board, Accounting Standards Codification 840, Leases, this reimbursement was recorded as a liability in loans payable and is being amortized over the life of the lease. At December 31, 2014, $108,000 is included in the balance sheet in current portion of loans payable and $358,000 is included in long-term portion of loans payable.
	In October 2013, the Company issued a convertible promissory note in the amount of $5.0 million to Fosun Industrial Co., Ltd., (the “Fosun Note”). The Fosun Note paid interest at 8% per annum.
	In the event of an IPO, the Fosun Note principal and accrued interest were to automatically convert to ordinary shares at a 10% discount to the IPO offering price. Fosun also had an option to elect, prior to July 1, 2014, to require the Company to create and then convert the Fosun Note to H preferred ordinary shares or pay in full all principal and interest outstanding on or before July 1, 2016. In the event of an IPO, the shares were to be subjected to restrictions prohibiting sale or transfer of more than one-third of the shares each year for the first three years following the offering.
	The feature which required automatic conversion upon an IPO was a redemption feature that met the definition of an embedded derivative requiring bifurcation from the Fosun Note. The Company determined there was no initial fair market value of the liability.
	In connection with the Company’s IPO in November 2013, the Fosun Note and interest of approximately $50,000 converted into 467,551 of the Company’s ordinary shares at a price per share which reflected a 10% discount to the IPO offering price of $12.00 per share. Upon conversion of the Fosun Note to ordinary shares, the derivative liability terminated. In connection with the IPO the Company marked the embedded derivative to market and recorded a $561,000 loss on the change in the fair value of the instrument.
	The Company has restricted cash in the amount of $80,000 pledged as collateral for procurement cards issued by a commercial bank.

Note_9_Share_Capital

Note 9 - Share Capital	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	9. Share capital
	As of December 31, 2014, the Company had 17,614,650 ordinary shares outstanding. In addition, there were a total of 1,877,142 options and a total of 275,500 restricted shares outstanding as of December 31, 2014.
	a. Preferred ordinary shares
	Just prior to the Company’s IPO in November 2013, all preferred ordinary shares were converted to ordinary shares on a one for one basis.
	The following is a summary of the Company’s preferred ordinary shares as of December 31, 2012:
		Preferred		Preferred ordinary
		ordinary		shares issued
		shares		and outstanding
		authorized
	A preferred ordinary		134,708		134,706
	B preferred ordinary		53,992		53,992
	D preferred ordinary		520,275		487,222
	E preferred ordinary		4,772,557		2,547,496
	F preferred ordinary		2,982,848		2,574,575
	G preferred ordinary		3,728,560		1,503,330
			12,192,940		7,301,321
	In February 2011 the Company issued 306,499 ordinary shares and 919,498 F preferred ordinary shares for consideration of $10 million cash in the third and final tranche of the F preferred ordinary share financing round.
	The Company issued 137,922 F preferred ordinary shares and 45,973 ordinary shares in March 2012 and 45,974 F preferred ordinary shares and 15,324 ordinary shares in April 2012 in the form of F Preferred Units as a financing fee for the Company’s $4 million issuance of the 2012 Notes.
	In June 2012, the Company issued 1,495,464 G preferred ordinary shares for consideration of $17 million in the first tranche of the G preferred ordinary share financing round. The Company issued an additional 7,882 G preferred ordinary shares in June 2012 as payment of interest on the 2012 Notes.
	On December 31, 2012, the Company held $8.1 million in cash received from investors related to the closing of the second and final tranche of the G preferred ordinary share financing round, which was recorded in shareholders’ equity. On January 4, 2013, the remaining cash was received from investors and the Company issued 966,417 G preferred ordinary shares to complete the second and final tranche of the G preferred ordinary share financing, raising a total of $11.0 million.
	The rights, preferences and privileges of the Company’s A preferred ordinary shares, B preferred ordinary shares, D preferred ordinary shares, E preferred ordinary shares, F preferred ordinary shares and G preferred ordinary shares (collectively, the preferred ordinary shares) were as follows:
	Voting and consent rights—The preferred ordinary shares in issue ranked pari passu with regards to voting rights. Holders of preferred ordinary shares were entitled to vote on all matters and were entitled to the number of votes equal to the number of ordinary shares into which each preferred ordinary share was then convertible. The consent of the holders of at least 60% of the E, F, and G preferred ordinary shares outstanding (taken together as a single class) was required for certain corporate actions including a deemed liquidation event, sale of all or a substantial portion of the Company’s assets or the creation of any debt of the Company in excess of $2,000,000. The approval of the holders of G preferred ordinary shares was required for any amendment or change to the Company’s articles of association that would be disproportionately adverse to the holders of G preferred ordinary shares and not similarly adverse to the rights of the holders of the other preferred ordinary shares and for the creation of any security convertible into a security having rights, preferences or privileges senior to the G preferred ordinary shares.
	Liquidation rights—Upon the liquidation of the Company, including certain transactions deemed to be a liquidation, the holders of G preferred ordinary shares and, as a separate class, the holders of F preferred ordinary shares had a liquidation preference to all other holders of preferred ordinary shares and ordinary shares, in an amount equal to, in the case of the G preferred ordinary shares, 1.25 times the original issue price of $11.399 per share, and, in the case of the F preferred ordinary shares, 1.50 times the original issue price of $8.153 per share. The liquidation preference for each of the holders of the G preferred ordinary shares and the F preferred ordinary shares was limited to 50% of the assets or sale amount available for distribution. In the event that the assets or sale amount was insufficient to make such distributions to the holders of G preferred ordinary shares and F preferred ordinary shares separately, then the holders of G preferred ordinary shares and F preferred ordinary shares would have participated, within their own classes, pro rata to their respective shareholdings of G preferred ordinary shares and F preferred ordinary shares, respectively. In the event that 50% of the assets or sale amount available for distribution was sufficient to satisfy one but not the other of the G preferred ordinary share preference and the F preferred ordinary share preference, separately, then any undistributed amount of assets or sale amount would be distributed to either the holders of G preferred ordinary shares or F preferred ordinary shares, as the case may be.
	Subsequent to the payments of the liquidation preferences of the G preferred ordinary shares and the F preferred ordinary shares, each holder of E preferred ordinary shares would receive an amount equal to the aggregate amount paid by such holder for such shares, which was $17.54 for the shares acquired in the first tranche in October 2007, $17.54 for the shares acquired in the second tranche in August 2008 and £0.006705 for the shares acquired pursuant to cashless exercise of warrants issued in October 2007.
	After the payments of the liquidation preferences to holders of G preferred ordinary shares, F preferred ordinary shares and E preferred ordinary shares in full, the remaining assets or sale amount would generally be paid, depending on the amount available for distribution, to holders of all shares based on their respective preferences or, if no preferences are applicable, to all holders on an as-converted basis.
	Transfer restrictions—The preferred ordinary shares could have been transferred to any person with the prior consent in writing of holders of shares entitled to cast 90% of the votes exercisable at a general meeting of the Company. The preferred ordinary shares could have been transferred at any time, without prior consent, to certain parties including, where the shares were held by individual members, to certain privileged relations and family trusts; where the shares were held by a company, to a member of the same group as such company; where the shares were held by an investment manager, to a participant or partner in or member of an investment fund which is managed by such investment manager, an investment fund whose business is managed by the investment manager, any other investment manager who manages the business of the investment fund in respect of which the shares are held, or any other person if required by a regulatory authority; where the shares were held by an investment fund, to a participant or partner in or member of such investment fund, any other investment fund whose business is managed by the same investment manager, or the investment manager who manages the business of the investment fund; where the shares were held by trustees under an employee trust, to the new trustees of that employee trust on any change of trustees or to any beneficiary of that employee trust.
	Anti-dilution rights—In the event of a relevant issue of securities at a price which, in the case of the G preferred ordinary shares, was less than the original issue price of $11.399 per share, the Company would have been required to issue to each holder of G preferred ordinary shares such number of ordinary shares as would result in such holder of G preferred ordinary shares holding such number of shares as would be held if the aggregate original issue price of $11.399 per share in respect of all G preferred ordinary shares then held by such holder was applied wholly in subscribing for the new shares at the weighted-average subscription price in respect of the relevant issue. In the event of a relevant issuance of securities at a price which, in the case of the F preferred ordinary shares and E preferred ordinary shares, was less than the original issue price of $8.153 per share, the Company would have been required to issue to each holder of E preferred ordinary shares and each holder of F preferred ordinary shares, with the exception of holders of F preferred ordinary shares who received such shares pursuant to the issuance of F preferred units, such number of ordinary shares as would result in such holders holding such number of shares as would be held if the aggregate original issue price of $8.153 per share in respect of all shares then held by such holder was applied wholly in subscribing for the new shares at the weighted-average subscription price in respect of the relevant issue. In June 2012, the anti-dilution rights resulted in the issuance of 817,761 ordinary shares to the holders of the E preferred ordinary shares. The transaction did not result in the recognition of a beneficial conversion feature as the effective conversion price of the shares exceeded the fair value of the ordinary shares at the date of issuance. Other than the issuance of share capital the transaction did not have accounting implications. In the event that additional shares had been issued as a result of the anti-dilution rights the Company would have recorded the issuance of share capital and assessed whether a beneficial conversion feature or other accounting implications were present. The anti-dilution rights did not preclude the classification of the shares as permanent equity.
	Conversion—Upon a conversion, each preferred ordinary share would automatically be converted to, re-designated as, and ranked pari passu with the ordinary shares then in issue immediately prior to and conditional upon a qualified listing on a one-for-one basis. Each preferred ordinary share was convertible into one ordinary share at any time at the holder’s request.
	The Company classified its convertible preferred ordinary shares as permanent equity, as they did not contain redemption rights or other terms that would require classification outside of permanent equity.
	b. Ordinary shares
	On November 21, 2013, the registration statement for the Company’s IPO was declared effective by the Securities and Exchange Commission. The Company sold 6,164,000 ordinary shares, at an initial public offering price of $12.00 per share, which included the exercise in full by the underwriters of their option to purchase up to 804,000 additional ordinary shares. Net proceeds from the IPO were approximately $63.9 million, after deducting underwriting discounts and commissions and estimated offering expenses. Following the Company’s IPO, the Company now has one class of ordinary shares authorized. As of December 31, 2014, there were 40,103,528 ordinary shares authorized and 17,614,650 ordinary shares issued and outstanding.

Note_10_Share_Option_and_Equit

Note 10 - Share Option and Equity Incentive Plans	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	10. Share option and equity incentive plans
	The Company has issued share options since 2003, and restricted shares since 2014, to incentivize employees and directors providing services to the Company. The Company currently maintains two equity compensation plans, the Amended and Restated 2008 Stock Incentive Plan and the 2013 Share Incentive Plan (the Plans). With the adoption of the 2013 Share Incentive Plan, the Company is no longer authorized to grant awards under the Amended and Restated 2008 Stock Incentive Plan.
	In November 2013, in connection with the Company’s IPO, the Company adopted the 2013 Share Incentive Plan (the 2013 Plan) which provides for the grant of share options, restricted shares, RSUs and other share-based awards to employees, officers, directors and consultants of the Company. The 2013 Plan authorizes the Company to grant up to 2,684,563 ordinary shares with such amount automatically increasing annually on each January 1st from January 1, 2015 to January 1, 2023 by 4% of the number of shares outstanding on the close of business of the immediately preceding December 31st, provided that the Board of Directors may limit the increase to a smaller amount or to no increase in any given year. At December 31, 2014, there were 1,589,956 shares available for future issuance under the 2013 Plan.
	Under both the 2008 Plan and the 2013 Plan, share options, and only under the 2013 Plan, restricted shares, have been granted to employees, officers and directors who provide services to the Company. Options generally vest based on the grantee’s continued service with the Company during a specified period following grant or, in rare instances, based on the achievement of performance or other conditions as determined by the Board of Directors, and expire after ten years. Option awards to employees generally vest monthly over a four year period; however, the vesting percentage remains 0% until the second anniversary of the vesting start date of the employee’s first option award under the 2008 Plan and either the second anniversary of the employee’s date of hire or the first day of the month following the second anniversary of the employee’s date of hire under the 2013 Plan. Restricted shares vest based on the grantees’ continued service with the Company during a specified period following grant as follows: 40% on the second anniversary of the grant date; 30% on the third anniversary of the grant date; and 30% on the fourth anniversary of the grant date.
	Prior to the Company’s IPO in November 2013, the Company engaged a third-party consultant to assist the Board of Directors in the determination of the estimated fair market value of the Company’s ordinary shares. The share price was determined by the Board of Directors using contemporaneous valuations. In certain instances, the valuation was delivered after the date the options were granted, but was retrospective to an earlier date specified in the valuation report.
	Transactions in the Company’s shares completed by independent investors represented the best indication of fair value of the securities. In addition, new rounds of venture capital financing, which reflected the expectations of independent investors with respect to the Company’s future performance, usually provided a good indication of the fair value of the ordinary shares. In this case, the fair value of the ordinary shares, was derived based on the price paid by the venture capital investors for the preferred ordinary shares, taking into account the differences in various rights and liquidation preferences between ordinary shares and the preferred ordinary shares. This is also known as the back-solve approach. In cases where there were no transactions or new financings, the use of a discounted cash flow analysis and guideline public firm multiples, adjusted for unique characteristics of the Company, were used as accepted methodologies.
	The fair value of the options was estimated at the grant date using the Black-Scholes option pricing model, taking into account the terms and conditions upon which options are granted. The fair value of the options is amortized on a straight-line basis over the requisite service period of the awards. The weighted-average grant date fair value per share relating to share options granted under the Plans during the years ended December 31, 2014, 2013, and 2012 was $9.32, $3.04, and $0.27, respectively. Share-based compensation expense for restricted shares is calculated based on the grant date market price of the shares and is also amortized on a straight-line basis over the requisite service period of the awards.
	The fair value of each option granted under the Plans has been calculated on the date of grant using the following assumptions:
			2014				2013			2012
	Expected dividend yield (%)			—				—			—
	Expected volatility (%)			46.87				47.78			49.43
	Risk-free interest rate (%)			1.86				1.38			1.03
	Expected life of option (years)			6.19				6.22			6.25
	Weighted-average share price ($)			19.66				5.86			0.6
	Weighted-average exercise price ($)			19.66				4.97			0.6
	Model used		Black-Scholes Model				Black-Scholes Model			Black-Scholes Model
	Expected dividend yield: The Company has not paid and does not anticipate paying any dividends in the foreseeable future.
	Risk-free interest rate: The Company determined the risk-free interest rate by using a weighted-average equivalent to the expected term based on the U.S. Treasury yield curve in effect as of the date of grant.
	Expected volatility: As the Company operated as a private company until November 2013, there is not sufficient historical volatility for the expected term of the options. Therefore, the Company used an average share price volatility over a historical period equal in length to the expected term, based on an analysis of reported data for a peer group of comparable companies which were selected based upon industry similarities. The Company intends to continue to use comparable companies in its volatility factor calculation until a sufficient amount of historical information regarding the volatility of its own share price becomes available.
	Expected term (in years): Expected term represents the period that the Company’s share option grants are expected to be outstanding. As the Company operated as a private company until November 2013, there is not sufficient historical share data to calculate the expected term of the options. Therefore, the Company elected to utilize the “simplified” method to value share option grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option.
	Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company estimates forfeitures based on historical termination behavior. For the years ended December 31, 2014, 2013, and 2012, a forfeiture rate of 5% was applied.
	The following table illustrates the number of ordinary shares and weighted-average exercise prices (WAEP) of, and movements in, share options during the year:
			Number of ordinary shares				WAEP in $
	Outstanding as of January 1, 2013			1,446,807			$	0.36
	Granted			312,198				5.12
	Exercised			(201,459	)			0.12
	Forfeited			(198,532	)			0.24
	Outstanding as of December 31, 2013			1,359,014				1.5
	Exercisable as of December 31, 2013			1,320,922			$	1.48
	Outstanding as of January 1, 2014			1,359,014			$	1.5
	Granted			633,823				19.66
	Exercised			(65,054	)			0.22
	Forfeited			(50,641	)			12.3
	Outstanding as of December 31, 2014			1,877,142				7.39
	Vested or expected to vest as of December 31, 2014			1,829,020			$	7.27
	Exercisable as of December 31, 2014			914,704			$	2.55
	The following table illustrates the number of restricted shares and weighted-average fair value (WAFV) of, and movements in, restricted shares during the year:
			Number of ordinary shares				WAFV in $
	Unvested balance as of January 1, 2014			-			$	-
	Granted			275,500				22.25
	Cancelled			-				-
	Vested			-				-
	Unvested balance as of December 31, 2014			275,500				22.25
	As of December 31, 2014, there was $4.9 million and $4.9 million of total unrecognized compensation cost related to non-vested share options and restricted shares, respectively, granted under the Plans. That cost for unvested share options and restricted shares is expected to be recognized over a weighted-average period of 2.5 years and 3.2 years, respectively.
	A summary of options outstanding and exercisable as of December 31, 2014, follows:
						Total options outstanding						Total options exercisable
	Exercise prices					Number of options			Weighted-average			Number of options		Weighted-average
									remaining life in					remaining life in
									years					years
	$0.00	-	$1.00				1,153,736						814,055
	$1.01	-	$5.00				42,049						7,901
	$10.00	-	$15.00				160,721						-
	$15.01	-	$20.00				159,262						24,258
	$20.01	-	$25.00				361,374						68,490
							1,877,142			7.9			914,704		6.9
	The aggregate intrinsic value of all share options outstanding under the Plans as of December 31, 2014 and 2013 is $15.7 million and $24.8 million, respectively. The aggregate intrinsic value of share options that were fully vested under the Plans as of December 31, 2014 is $10.8 million.
	During the years ended December 31, 2014, 2013, and 2012, current and former employees of the Company exercised a total of 65,054, 201,459, and 9,378 share options, respectively, resulting in total proceeds of $14,000 during 2014, $24,000 during 2013 and less than $1,000 during 2012. The intrinsic value of share options exercised during the years ended December 31, 2014, 2013, and 2012 was $0.9 million, $3.9 million, and $6,000, respectively. In accordance with Company policy, the shares were issued from a pool of shares reserved for issuance under the Plans described above.
	A summary of the activity of the Company’s unvested share options is as follows:
			Number of shares				Weighted-average grant
							date fair value
	Balance as of December 31, 2013			761,840			$	1.43
	Granted			633,823				9.32
	Vested			(385,042	)			2.66
	Forfeited			(48,182	)			6.06
Balance as of December 31, 2014			962,439				5.92
The total fair value of shares vested for the years ended December 31, 2014, 2013, and 2012 was $1.0 million, $42,000, and $12,000, respectively.
The impact on the Company’s results of operations from share-based compensation for the years ended December 31, 2014, 2013, and 2012, was as follows:
(in thousands)		2014				2013			2012
Cost of revenue		$	330			$	5		$	2
Research and development			87				1			4
Sales and marketing			949				26			18
General and administrative			1,155				108			55
Total share-based compensation		$	2,521			$	140		$	79
For the year ended December 31, 2014, the Company incurred shared-based compensation expense related to share options and restricted shares of approximately $1.6 million and $0.9 million, respectively. For the years ended December 31, 2013 and 2012, the Company only incurred shared-based compensation expense related to share options.

Note_11_Net_Loss_Per_Share

Note 11 - Net Loss Per Share	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	11. Net loss per share
	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share:
			Year ended December 31,
	($ in thousands)		2014				2013				2012
	Numerator:
	Net loss attributable to ordinary shareholders		$	(22,174	)		$	(8,664	)		$	(14,883	)
	Denominator:
	Weighted-average ordinary shares outstanding-basic			17,310,148				3,830,837				1,763,728
	Dilutive effect of ordinary share equivalents resulting from ordinary share options, ordinary share warrants and preferred ordinary shares (as converted)			—				—				—
	Weighted-average ordinary shares outstanding-diluted			17,310,148				3,830,837				1,763,728
	The following numbers of outstanding ordinary share options, ordinary share warrants, preferred ordinary shares (on an “as converted to ordinary shares” basis) and restricted shares were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive:
		Year ended December 31,
		2014				2013				2012
	Options to purchase ordinary shares		1,194,612				1,252,790				1,129,657
	Ordinary share warrant		—				19,473				3,682
	Preferred ordinary shares (as converted)		—				—				7,301,371
	Unvested restricted shares		275,500				—				—

Note_12_Related_Party_Transact

Note 12 - Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related party transactions
	In October 2013, the Company issued a convertible promissory note in the amount of $5.0 million to Fosun Industrial Co., Ltd., (the Fosun Note). The Fosun Note paid interest at 8% per annum. In connection with the Company’s IPO in November 2013, the Fosun Note and interest of approximately $50,000 automatically converted into 467,551 of the Company’s ordinary shares at a price per share which reflected a 10% discount to the IPO offering price of $12.00 per share. The shares are subject to restrictions prohibiting sale or transfer of more than one-third of the shares each year for the first three years following the IPO. The feature which required automatic conversion upon an IPO was a redemption feature that met the definition of an embedded derivative requiring bifurcation from the Fosun Note. The Company determined there was no initial fair market value of the liability. Upon conversion of the Fosun Note to ordinary shares, the derivative liability terminated. In connection with the IPO the Company marked the embedded derivative to market and recorded a $561,000 loss on the change in the fair value of the instrument.
	Revenue on sales to Fosun subsequent to the issuance of the promissory note was $8.5 million in 2014 and $1.3 million in 2013. The balance of accounts receivable from Fosun at December 31, 2014 was $1.4 million and the balance at December 31, 2013 was immaterial.

Note_13_Income_Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. Income taxes
	The components of profit (loss) before income taxes are as follows for the years ended December 31:
	(in thousands)	2014			2013			2012
	Domestic (United Kingdom)	$	(158	)	$	4,915		$	(2,754	)
	Foreign (United States)		(21,862	)		(13,487	)		(12,280	)
	Loss before income taxes	$	(22,020	)	$	(8,572	)	$	(15,034	)
	The components for the income tax expense (benefit) are as follows for the years ended December 31:
	(in thousands)	2014			2013			2012
	Current:
	Federal	$	—		$	—		$	—
	UK		—			—			(173	)
	Japan		119			47			—
	State		35			45			22
	Total current provision		154			92			(151	)
	Deferred:
	Federal		—			—			—
	UK		—			—			—
	State		—			—			—
	Total deferred benefit		—			—			—
		$	154		$	92		$	(151	)
	Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
	The Company’s effective income tax rate differs from the statutory domestic (United Kingdom) income tax rate as follows for the years ended December 31:
		2014			2013			2012
	Income tax rate		21.5	%		23.3	%		20	%
	U.K. research and development credit		1.7			—			1.1
	Other		(1.2	)		(0.6	)		(0.3	)
	Effect of foreign tax rate differential		17.9			16.9			15.9
	Valuation allowance		(40.6	)		(40.6	)		(35.7	)
	Effective income tax rate		(0.7	)%		(1.0	)%		1	%
	The Company is headquartered in the United Kingdom and the effective U.K. corporate tax rate for the years ended December 31, 2014, 2013, and 2012 was 21.5%, 23.3%, 20%, respectively. The U.S. federal corporate tax rate was 34% for the years ended December 31, 2014, 2013, and 2012. The Company is subject to taxation in the U.S. and various state, local, and foreign jurisdictions. The Company remains subject to examination by various tax authorities for tax years 2011 through 2014. With a few exceptions, the Company is no longer subject to examinations by tax authorities for the tax years 2010 and prior. However, net operating losses from the tax years 2010 and prior would be subject to examination if and when used in a future tax return to offset taxable income. The Company’s policy is to recognize income tax related penalties and interest, if any, in its provision for income taxes and, to the extent applicable, in the corresponding income tax assets and liabilities, including any amounts for uncertain tax positions.
	Significant components of the Company’s deferred tax assets are as follows for the years ended December 31:
	(in thousands)	2014			2013
	Deferred tax assets:
	Long term deferred tax assets:
	U.S. federal net operating losses	$	24,136		$	16,897
	State net operating loss (net of federal)		3,001			1,659
	U.S. federal research and development credit		110			—
	U.K. net operating loss		7,800			7,408
	Share options		567			112
	Accrued liabilities		97			233
	Other		78			127
	Short term deferred tax assets:
	Accrued liabilities		—			373
	Other assets		—			9
	Total deferred tax assets		35,789			26,818
	Valuation allowance		(35,361	)		(26,413	)
	Total deferred tax assets	$	428		$	405
	Deferred tax liabilities:
	Long term deferred tax liabilities:
	Other assets	$	(428	)	$	(405	)
	Total deferred tax liabilities	$	(428	)	$	(405	)
	For the years ended December 31, 2014 and 2013, the Company had United Kingdom Net Operating Losses (U.K. NOLs) of $39.0 million and $37.0 million, respectively. U.S. federal net operating loss carryforwards for the years ended December 31, 2014 and 2013 were $71.9 million and $49.7 million, respectively. U.S. State net operating loss carryforwards for the years ended December 31, 2014 and 2013 were $63.6 million and $45.1 million, respectively. The federal and state NOLs include approximately $0.8 million of deductions related to the exercise of stock options subsequent to the adoption of ASC 718, “Stock Compensation.” This amount represents an excess tax benefit as defined under ASC 718 and has not been included in the gross deferred tax asset reflected for NOLs.
	The federal and state net operating loss carryforwards begin to expire in 2027 and 2030, respectively and the U.K. NOLs can be carried forward indefinitely.
	For financial reporting purposes, a valuation allowance has been recognized to offset the deferred tax assets related to the carryforwards. The utilization of the loss carryforwards to reduce future income taxes will depend on the Company’s ability to generate sufficient taxable income prior to the expiration of the loss carryforwards. To date the Company has incurred significant operating losses. In addition, the maximum annual use of net operating losses and research credit carryforwards is limited in certain situations where changes occur in stock ownership.
	The following table reflects the rollforward of the Company’s valuation allowance:
	(in thousands)	2014			2013			2012
	Beginning of year (January 1)	$	26,413		$	22,929		$	17,556
	Increase in valuation allowance		8,948			3,484			5,373
	End of year (December 31)	$	35,361		$	26,413		$	22,929
	The Company reviewed its historical tax filings and tax positions and has determined no material uncertain tax positions exist at December 31, 2014 and 2013. The Company continues to monitor its tax filings and positions.
	The Company generates research and development credits in the United Kingdom which are refundable if a current year loss is incurred. In the United Kingdom for the year ended December 31, 2012 the Company was reimbursed $0.2 million, for research and development tax credits. These were recorded as a reduction against income tax expense. For the year ended December 31, 2014 and 2013, no such amounts were reimbursed for research and development tax credits.

Note_14_Intellectual_Property_

Note 14 - Intellectual Property - License Agreements	12 Months Ended
	Dec. 31, 2014
License Agreements Tex Block [Abstract]
License Agreements Tex Block	14. Intellectual property—license agreements
	The Company entered into three license agreements by which it has secured certain patent rights that are necessary to make, use and sell the T-SPOT.TB test. One of these license agreements, with Isis, was terminated in connection with the assignment by Isis to the Company of certain intellectual property rights in November 2013. The Company has ongoing obligations to make certain payments to Isis while the assigned patents remain in force in certain countries. The Company’s existing license agreements related to its T-SPOT.TB test, as well as its previous license from Isis, are generally exclusive in the stated field, cover a worldwide territory, are royalty-bearing and give the Company the right to grant sublicenses. The Company has minimum royalty obligations under each existing license agreement, which continue so long as patents licensed under the agreement remain unexpired. The minimum contractual royalty payments, including ongoing minimum payment obligations to Isis, after December 31, 2014 and 2013 are set forth in the commitments and contingencies table in Note 16 “Commitments and contingencies” to these consolidated financial statements.
	The Company incurs royalties under each existing license agreement, has incurred royalties under the Isis license agreement, and will incur continuing payment obligations to Isis that are treated as royalties in these financial statements, based on its product and service revenue. The aggregate royalty expense relating to the three license agreements amounted to $4.8 million, $3.7 million, and $2.4 million for the years ended December 31, 2014, 2013, and 2012, respectively. The Company paid other license-related expenses, including patent prosecution expenses, milestone payments and assignment fees due to these licensors, amounting to $0.1 million, $0.3 million, and $0.1 million for the years ended December 31, 2014, 2013, and 2012, respectively. The aggregate royalty rate paid by the Company in the years ended December 31, 2014, 2013, and 2012, as a percentage of the gross product and service revenue of the Company, was 10%, 10%, and 11%, respectively.

Note_15_Employee_Benefit_Plans

Note 15 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block Supplement [Abstract]
Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]	15. Employee benefit plans
	In the United States, the Company has adopted a defined contribution plan (the U.S. Plan) which qualifies under Section 401(k) of the Internal Revenue Code. All U.S. employees of the Company who have attained 21 years of age are eligible for participation in the U.S. Plan upon employment. The effective date of the U.S. Plan was January 1, 2008. Under the U.S. Plan, participating employees may defer up to the Internal Revenue Service annual contribution limit. The Company does not match employee contributions.
	In the United Kingdom, the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue & Customs. The U.K. Plan allows all U.K. employees to contribute a minimum of 5% of salary with no maximum limit. The contribution is matched by the Company, up to a maximum of 5% of salary. The Company paid to the U.K. Plan $0.5 million in matching contributions in the year ended December 31, 2014, and $0.4 million in each of the years ended December 31, 2013 and 2012.

Note_16_Commitments_and_Contin

Note 16 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	16. Commitments and contingencies
	Operating leases
	At December 31, 2014, the Company leases facilities under four non-cancelable operating leases, with terms that expire between 2018 and 2021. The Company leases office, storage, laboratory and manufacturing space in Abingdon, U.K., which leases are due to expire on January 31, 2018 (with respect to the storage facility) and June 11, 2019. On March 1, 2013, the Company signed a five year lease for its U.S. corporate headquarters in Marlborough, Massachusetts. During June 2013, the Company moved into this facility and vacated the old facility prior to lease expiration on June 30, 2013. The new lease term runs from June 2013 to October 2018. The Company leases laboratory space in Memphis, Tennessee, which lease is due to expire on December 31, 2021. For property in the United States, the Company has bank balances pledged as security as described in Note 1, “Description of business and significant accounting policies—Restricted cash” to these consolidated financial statements.
	Future minimum lease payments required under the non-cancelable operating leases in effect as of December 31, 2014 are as follows:
	(in thousands)	December 31,
		2014
	Year 1	$	975
	Year 2		982
	Year 3		843
	Year 4		776
	Year 5		261
	Thereafter		—
	Total minimum lease payments	$	3,837
	Rent expense is calculated on a straight-line basis over the term of the lease. Rent expense recognized under operating leases totaled $0.7 million for each of the years ended December 31, 2014, 2013, and 2012, respectively.
	Purchase commitments
	The Company has license agreements with third parties that provide for minimum royalty, license, and exclusivity payments to be paid by the Company for access to certain technologies. In addition, the Company pays royalties as a percent of revenue as described in Note 14, “Intellectual property—license agreements” to these consolidated financial statements. In addition, the Company has outstanding purchase obligations to its suppliers.
	Future minimum payments required under license agreements and supplier purchase obligations in effect as of December 31, 2014 are as follows:
	(in thousands)	License agreements		Supplier purchase obligations		Total
	Year 1	$	1,688	$	3,180	$	4,868
	Year 2		1,688		250		1,938
	Year 3		1,688		250		1,938
	Year 4		1,688		250		1,938
	Year 5		1,676		—		1,676
	Thereafter		25		—		25
	Total minimum license payments	$	8,453	$	3,930	$	12,383
	Legal contingencies
	The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company’s business, financial condition, results of operations or cash flows.
	Indemnification
	In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but that have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations.
	In accordance with its articles of association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date, and the Company has director and officer insurance that may enable it to recover a portion of any amounts paid for future potential claims.

Note_17_Geographic_Revenue_and

Note 17 - Geographic Revenue and Long-Lived Assets Distribution	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	17. Geographic revenue and long-lived assets distribution
	The Company is domiciled in the United Kingdom and operates in three geographies: the United States, Europe and the Rest of the World (ROW), and Asia. Revenue and long-lived assets for the years ended December 31, 2014, 2013, and 2012 are shown in the following table:
		Revenue						Long-lived assets
		Year ended December 31,						Year ended December 31,
	(in thousands)	2014		2013		2012		2014		2013
	United States	$	22,537	$	17,345	$	10,366	$	3,198	$	2,496
	United Kingdom		2,971		2,795		2,466		928		360
	Europe & ROW (excluding United Kingdom)		4,248		4,362		4,064		259		—
	Europe & ROW		7,219		7,157		6,530		1,187		360
	Asia		19,749		14,282		3,789		152		108
	Total	$	49,505	$	38,784	$	20,685	$	4,537	$	2,964
	China represented approximately 43%, 44%, and 82% of Asia revenue in 2014, 2013, and 2012, respectively. Japan represented approximately 54%, 55%, and 7% of Asia revenue in 2014, 2013, and 2012, respectively.

Note_18_Acquisition_Activity

Note 18 - Acquisition Activity	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	18. Acquisition activity
	During November 2012 the Company entered into an agreement to acquire the assets of another corporation. As part of the process, in December 2012 the Company deposited $0.3 million in an escrow account with an escrow agent that was recorded as restricted cash on the balance sheet as of December 31, 2012. In January 2013 the Company’s agreement to purchase the assets was terminated and, in connection therewith the Company received the $0.3 million cash held in escrow. In February 2013 the Company received a breakup fee in the amount of $0.2 million, which was recorded in other income, and authorized expense reimbursements of $0.3 million, recorded as an offset to the related general and administrative expenses.
	On July 31, 2014 (“date of the acquisition”), the Company acquired substantially all of the assets of Boulder, a privately owned company developing immunology-based assays for autoimmune and inflammatory conditions/diseases. The assets acquired primarily relate to assays for Lyme disease and gout and an assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response that was acquired in conjunction with the Boulder acquisition. As part of the transaction, Boulder transferred to the Company all shares of capital stock in its wholly-owned subsidiary, Boulder Diagnostics Europe GmbH, such that the Company has become the sole owner of Boulder Diagnostics Europe GmbH.
	The terms of the purchase agreement provided for an upfront payment of $1.7 million and contingent purchase price consideration consisting of future potential milestone payments totaling up to $6.1 million in respect of the Lyme disease and gout assays at any time on or prior to July 31, 2024. The milestone payments consist of up to $400,000 for the completion of studies related to acquired technologies, up to $700,000 for the development of diagnostic test kits, $500,000 for the first patient enrolled in an Institutional Review Board approved study, up to $1.5 million for the issuance of patents, and up to $3.0 million for approvals or clearances by the U.S. Food and Drug Administration. The Company has determined that this liability is a Level 3 fair value measurement within the FASB’s fair value hierarchy and the fair value has been estimated to be $1.2 million on the date of acquisition based on significant assumptions, including the probabilities of milestone occurrence, the expected timing of milestone payments, and a discount rate of 15%. Such liability is adjusted to fair value at each reporting date, with the adjustment reflected in general and administrative expenses. See Note 2 “Fair value measurement” for information pertaining to changes in the fair value of this liability.
	The acquisition of Boulder was accounted for under the acquisition method of accounting and the purchase price allocation was provisionally prepared during the third quarter of 2014. These provisional amounts have been finalized during the fourth quarter of 2014. Total consideration was (in thousands):
	Cash consideration	$	1,724
	Estimated fair value of contingent consideration		1,247
	Total consideration transferred	$	2,971
	$183,200 of the cash consideration has been placed in an escrow account for a period of 24 months as security for any undisclosed liabilities and as indemnification for certain items. The Company paid approximately $181,000 in transaction costs associated with this transaction, which is included in general and administrative expense in the consolidated statement of operations.
	The following table summarizes the purchase price of the Boulder acquisition, the fair value of identified assets acquired and liabilities assumed at the acquisition date (in thousands):
	Assets acquired:
	Cash	$	8
	Accounts receivable		15
	Inventory		40
	Prepaid expenses and other		12
	Property and equipment		359
	In-process research and development		2,627
	Total assets acquired		3,061
	Liabilities assumed:
	Accounts payable		(97	)
	Accrued liabilities		(14	)
	Other current liabilities		(34	)
	Total liabilities assumed		(145	)
	Net assets acquired		2,916
	Add: goodwill		55
	Total consideration transferred	$	2,971
	On the date of the acquisition the fair value of IPR&D acquired was determined to be $2.6 million ($1.8 million for the Lyme disease assay, $0.5 million for the assay to help select biologics for autoimmune disease based on monitoring and prognosis of drug response that was acquired in conjunction with the Boulder acquisition, and $0.3 million for the gout assay) using the excess earnings method with significant inputs, including estimates of the timing and cost required for product approval, revenue growth, gross margin, operating expenses and a 15% discount rate, that are not observable. The Company considers the fair value of IPR&D to be a Level 3 fair value asset due to the significant estimates and assumptions used by management in establishing the estimated fair value.
	Goodwill and IPR&D are indefinite-lived intangible assets and are not amortized. Rather, they are reviewed for impairment at least annually. There was no evidence of any impairment indicators at December 31, 2014 and there were no impairment charges during the year ended December 31, 2014.
	Actual results of operations of Boulder are included in the financial statements from the date of the acquisition, including revenues in the amount of $42,000 and losses from operations of $396,000. The functional currency for Boulder in Germany is the Euro.
	Pro Forma Information:The unaudited pro forma condensed consolidated statement of operations of the Company, set forth below, gives effect to the Company’s acquisition of Boulder, using the acquisition method as if it occurred on January 1, 2013. These amounts are not necessarily indicative of the consolidated results of operations for future years or actual results that would have been realized had the acquisition occurred as of the beginning of each such year:
		Year Ended December 31,
	(in thousands, except share and per share data)	2014			2013
	Total revenues	$	49,577		$	38,923
	Net loss	$	(22,399	)	$	(9,669	)
	Net loss per share—basic and diluted	$	(1.29	)	$	(2.52	)
	Weighted average shares outstanding—basic and diluted		17,310,148			3,830,837

Note_19_Restructuring

Note 19 - Restructuring	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	19. Restructuring
	During the fourth quarter of 2014, the Company closed the facilities that had been used by Boulder (see Note 18 “Acquisition activity”), terminated four employees, and consolidated the research and development activities that had been performed at those locations to the Company’s Abingdon, U.K. and Memphis, Tennessee facilities. As a result of these actions, the Company recorded in research and development expense a restructuring charge of $182,000. A summary of these charges and payments made to date are included in the below table. Accrued restructuring costs at December 31, 2014 are included in accrued liabilities in the accompanying balance sheet.
	(in thousands)	Abandonment of Excess Facilities			Relocation Costs			Severance			Total
	Balance at December 31, 2013	$	—		$	—		$	—		$	—
	Costs incurred in 2014		86			70			16			172
	Payments		(44	)		(42	)		(16	)		(102	)
	Balance at December 31, 2014	$	42		$	28		$	—		$	70
	In addition to the items listed above, the Company recorded charges totaling $10,000 to write-off abandoned equipment.

Note_20_Subsequent_Events

Note 20 - Subsequent Events	12 Months Ended
	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	20. Subsequent events
	On January 29, 2015, the Company entered into an Underwriting Agreement with several Underwriters, relating to the Offering of 4,255,319 Shares, at an Offering Price to the public of $11.75 per Share. The Underwriters agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $11.045 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to an additional 638,297 Option Shares at the Offering Price, less underwriting discounts and commissions. On January 30, 2015, the Underwriters exercised their option to purchase the Option Shares in full. The gross proceeds to the Company from the sale of the Shares and the Option Shares were approximately $57.5 million and the Company received net proceeds of approximately $53.7 million after deducting underwriting discounts and commissions and estimated aggregate offering expenses payable by the Company. The Offering closed on February 4, 2015.
	Effective January 15, 2015, the Remuneration Committee of the Board of Directors approved grants to employees for up to 355,509 share options from the Oxford Immunotec Global PLC 2013 Share Incentive Plan. These grants were issued to employees in the first quarter of 2015.

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Basis of presentation, accounting principles and principles of consolidation
	The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP), and include the financial statements of Oxford Immunotec Global PLC, a company incorporated in England and Wales and its wholly-owned subsidiaries, collectively referred to as the Company. The financial statements include the results of Oxford Immunotec Limited and its consolidated subsidiaries for the period prior to the completion of the Scheme of Arrangement, as well as the results of Oxford Immunotec Global PLC and its consolidated subsidiaries for the period after completion of the Scheme of Arrangement. All intercompany accounts and transactions have been eliminated upon consolidation
Segment Reporting, Policy [Policy Text Block]	Segment reporting
	The Company operates in one operating segment. The Company’s chief operating decision maker (the CODM), its chief executive officer, manages the Company’s operations on an integrated basis for the purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews separate revenue information for the Company’s product and service offerings and for each country, while all other financial information is on a combined basis. While the Company’s principal operations and decision-making functions are located in both the United States and United Kingdom, the CODM makes decisions on a global basis. Accordingly, the Company has determined that it operates in a single reporting segment
Use of Estimates, Policy [Policy Text Block]	Use of estimates
	The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and that affect the reported amounts of revenue and expenditures during the reporting periods. Actual results could differ from those estimates and assumptions used
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation
	The functional currency for Oxford Immunotec Global PLC is the U.S. Dollar. The functional currency for the Company’s operating subsidiaries are the Pound Sterling for Oxford Immunotec Limited, the U.S. Dollar for Oxford Immunotec Inc., the Yen for Oxford Immunotec K.K., and the Euro for Boulder Diagnostics Europe GmbH. Revenue and expenses of foreign operations are translated into U.S. Dollars at the average rates of exchange during the year. Assets and liabilities of foreign operations are translated into U.S. Dollars at year-end rates. The Company reflects resulting translation gains or losses in accumulated other comprehensive income, which is a component of shareholders’ equity. The Company does not record tax provisions or benefits for the net changes in foreign currency translation adjustments, as the Company intends to permanently reinvest undistributed earnings in its foreign subsidiaries.
	Realized and unrealized foreign currency transaction gains or losses, arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies, are included in “Other income (expense)” in the consolidated statements of operations
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of risks
	The Company derives product revenue from the sale of its T-SPOT.TB diagnostic test kits and related accessories to a broad range of customers including: hospitals, public health departments, commercial testing laboratories, importers and distributors. Importers and distributors sell to third parties including end-user customers in specific territories.
	In the year ended December 31, 2014, the Company had two product customers that represented more than 10% of the Company’s annual revenue. The Company’s Chinese distributor, Shanghai Fosun Long March Medical Science Co. Ltd., or Fosun, represented 17% of annual revenue and the Company’s Japanese importer, Riken Genesis Co., Ltd. represented 14% of annual revenue. The loss of either of these product customers could have a material impact on the Company’s operating results.
	In October 2013, the Company issued a convertible promissory note in the amount of $5.0 million to Fosun Industrial Co., Ltd., (the Fosun Note). The Fosun Note paid interest at 8% per annum. In connection with the Company’s IPO in November 2013, the Fosun Note and interest of approximately $50,000 converted into 467,551 of the Company’s ordinary shares at a price per share which reflected a 10% discount to the IPO offering price of $12.00 per share. Upon conversion of the Fosun Note to ordinary shares, the derivative liability terminated. In connection with the IPO the Company marked the embedded derivative to market and recorded a $561,000 loss on the change in the fair value of the instrument.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents
	The Company maintains its available cash balances in cash, money market funds primarily invested in U.S. government securities, and bank savings accounts in the United States, United Kingdom, Germany, and Japan. The Company maintains deposits in government insured financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted cash
	As of December 31, 2014 and 2013, U.S. bank balances totaling $312,000 and $399,000, respectively, were pledged as security for the Company’s U.S. office and laboratory space operating leases.
	As of December 31, 2014 and 2013, the Company had restricted cash of less than $100,000 pledged as collateral for procurement cards issued by a U.S. commercial bank
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Accounts receivable
	Accounts receivable are primarily amounts due from hospitals, public health departments, commercial testing laboratories, distributors and universities in addition to third party payors such as commercial insurance companies and government programs (Medicare and Medicaid).
	Accounts receivable are reported net of an allowance for uncollectible accounts. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management’s analysis of current and past due accounts, collection experience and other relevant information. The Company’s provision for uncollectible accounts is recorded as a bad debt expense and included in general and administrative expenses. Although the Company believes amounts provided are adequate, the ultimate amounts of uncollectible accounts receivable could be in excess of the amounts provided
Inventory, Policy [Policy Text Block]	Inventory
	Inventory consists of finished goods and raw materials. The Company does not maintain work in progress balances as the nature of the manufacturing process does not allow for test kits to be left in a partially manufactured state. Inventory is removed at cost. Inventory is stated at the lower of cost or market. Cost is determined by the actual cost of components by batch plus estimated labor and overhead costs per unit. Market value is based on an estimated selling price less any costs expected to be incurred to completion and sale. The Company reviews the components of its inventory on a periodic basis for excess, obsolete or impaired inventory, and records a reserve for the identified items. At December 31, 2014 and 2013, the Company determined no inventory reserve was required
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment
	Property and equipment are stated at cost. Property and equipment includes specialized shipping containers provided to customers, in the United States, for transporting samples to its laboratory for testing. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease.
	Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three to ten years for laboratory equipment, office equipment and furniture and fixtures and three years for software and specialized shipping containers.
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition
	The Company derives product revenue from the sale of its T-SPOT.TB diagnostic test kits and related accessories to a broad range of customers including hospitals, public health departments, commercial testing laboratories, importers and distributors.
	Product revenue is generally paid directly by the customer and is recognized on an accrual basis when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) the product has been shipped or delivered in accordance with the shipping terms of the arrangement; (3) the price is fixed or determinable and known at time of shipment; and (4) collectability is reasonably assured.
	For products sold in Japan, the price currently only becomes determinable upon the wholesaler dispatching kits to satisfy a firm order from its customer and, as a result, this is when the Company recognizes revenue for such sales.
	No product return rights are extended to customers of the Company.
	The Company derives service revenue from its diagnostic laboratories in the United States and in the United Kingdom where the Company performs its T-SPOT.TB test on samples sent by customers to its laboratory facilities.
	Service revenue in the United Kingdom and revenue from direct bill customers in the United States are recognized on an accrual basis when the following revenue recognition criteria are met: (1) persuasive evidence that an arrangement exists; (2) when the diagnostic result has been delivered; (3) the price is fixed or determinable; and (4) collectability is reasonably assured. This service revenue is referred to as “direct-bill” sales because the Company receives payment directly from the ordering entity.
	In the United States, the Company also generates revenue from payments that are received from a variety of third-party payors, including government programs (Medicare and Medicaid) and commercial insurance companies, each with different billing requirements. Revenue from tests paid by third-party payors is recognized on an accrual basis based on the Company’s historical collection experience.
	Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations
Cost of Sales, Policy [Policy Text Block]	Cost of revenue: cost of product and cost of service
	Cost of product revenue consists primarily of costs incurred in the production process, including costs of raw materials and components, assembly labor and overhead, quality costs, royalties paid under licensing agreements, the U.S. medical device excise tax and packaging and delivery costs.
	Cost of service revenue consists primarily of costs incurred in the operation of the Company’s diagnostic laboratories including labor and overhead, kit costs, quality costs, consumables used in the testing process and packaging and delivery costs.
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and handling
	The Company does not normally bill its service customers for shipping and handling charges. Charges relating to inbound and outbound freight costs are incurred by the Company and recorded within cost of service.
	The Company generally bills product customers for shipping and handling and records the customer payments as product revenue. The associated costs are recorded as cost of product sold
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of long-lived assets
	The Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may be impaired, and assesses their recoverability based upon anticipated future cash flows. If changes in circumstances lead the Company to believe that any of its long-lived assets may be impaired, the Company will (a) evaluate the extent to which the remaining book value of the asset is recoverable by comparing the future undiscounted cash flows estimated to be associated with the asset to the asset’s carrying amount and (b) write-down the carrying amount to market value to the extent necessary. There has been no impairment of long-lived assets to date
Business Combinations Policy [Policy Text Block]	Business combinations
	For acquisitions meeting the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. The fair value of the assets acquired and liabilities assumed is typically determined by using either estimates of replacement costs or discounted cash flow valuation methods.
	When determining the fair value of tangible assets acquired, the Company estimates the cost using the most appropriate valuation method with assistance from independent third party specialists. When determining the fair value of intangible assets acquired, the Company uses judgment to estimate the applicable discount rate, growth rates and the timing and amount of future cash flows. The fair value of assets acquired and liabilities assumed is typically determined by management using the assistance of independent third party specialists. The assumptions used in calculating the fair value of tangible and intangible assets represent the Company’s best estimates. If factors change and the Company were to use different assumptions, valuations of tangible and intangible assets and the resulting goodwill balance related to the business combination could be materially different.
	The terms of the purchase agreement with Boulder included contingent purchase price consideration consisting of future potential milestone payments totaling up to $6.1 million at any time on or prior to July 31, 2024. The milestone payments consist of completion of studies related to acquired technologies, development of diagnostic test kits, patient enrollment in an Institutional Review Board approved study, issuance of patents, and approvals or clearances by the U.S. Food and Drug Administration. The fair value of future potential milestone payments was determined based upon a probability weighted analysis of expected future milestone payments to be made to the seller. This analysis includes significant management judgments related to the probabilities of success assigned to the milestones and to the discount rate utilized in the calculations
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and indefinite-lived intangible assets
	Goodwill
	Goodwill is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate that all, or a portion, of the carrying value of the reporting unit may no longer be recoverable, using the two-step impairment review. Under this method, the Company compares the fair value of the goodwill to its carrying value. If the fair value is less than the carrying amount, a more detailed analysis is performed to determine if goodwill is impaired. An impairment loss, if any, is measured as the excess of the carrying value of goodwill over the fair value of goodwill. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads it to determine that it is more likely than not (that is, a likelihood of more than 50%) that goodwill is impaired. If the Company chooses to first assess qualitative factors and it is determined that it is not more likely than not goodwill is impaired, it is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which it may choose to do in some periods but not in others.
	Indefinite-lived intangible assets
	The Company’s indefinite-lived intangible assets consist of acquired in-process research and development (“IPR&D”), related to the Company’s business combination with Boulder, which were recorded at fair value on the acquisition date. IPR&D intangible assets are considered indefinite-lived intangible assets until completion or abandonment of the associated research and development efforts. IPR&D is not amortized but is reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may be impaired. If the fair value of the intangible asset is less than the carrying amount, the Company performs a quantitative test to determine the fair value. The impairment loss, if any, is measured as the excess of the carrying value of the intangible asset over its fair value. The Company also has the option to first assess qualitative factors to determine whether the existence of events or circumstances leads it to determine that it is more likely than not (that is, a likelihood of more than 50%) that its indefinite-lived intangible asset is impaired. If the Company chooses to first assess qualitative factors and it is determined that it is not more likely than not its indefinite-lived intangible asset is impaired, it is not required to take further action to test for impairment. The Company also has the option to bypass the qualitative assessment and perform only the quantitative impairment test, which it may choose to do in some periods but not in others.
	The determinations as to whether, and, if so, the extent to which, acquired IPR&D become impaired are highly judgmental and based on significant assumptions regarding the projected future financial condition and operating results, changes in the manner of the use and development of the acquired assets, the Company’s overall business strategy, and regulatory, market and economic environment and trends.
	Definite-lived intangible assets
	Intangible assets include technology licenses which are capitalized and amortized over estimated useful lives (generally in the range of five to ten years) using the straight-line method. On an ongoing basis, the Company assesses the recoverability of its intangible assets by determining its ability to generate undiscounted future cash flows sufficient to recover the unamortized balances over the remaining useful lives. Intangible assets determined to be unrecoverable are expensed in the period in which the determination is made.
Derivatives, Policy [Policy Text Block]	Derivative financial instruments
	The Company does not use derivative instruments to hedge exposures to cash flow, market, interest rate or foreign currency risks.
	The Company reviews the terms of the shares and warrants it issues and its convertible promissory notes to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument.
	Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as other income or expense. When equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value.
Fair Value Measurement, Policy [Policy Text Block]	Fair value of financial instruments
	The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of December 31, 2014 and 2013, the Company’s financial instruments consist of cash and cash equivalents, accounts receivable, prepaid expenses, and other accounts payable, accrued liabilities, and loans payable. As of December 31, 2013, the Company’s financial instruments also included ordinary share warrants. See Note 2 “Fair value measurement,” to the consolidated financial statements for further information on the fair value of the Company’s financial instruments.
Research and Development Expense, Policy [Policy Text Block]	Research and development expenses
	Research and development expenses include all costs associated with the development of the Company’s T-SPOT technology platform and potential future products including new diagnostic tests that utilize the T-SPOT technology platform and are charged to expense as incurred. In addition, with the acquisition of Boulder in the third quarter of 2014, the Company has expanded its research efforts to include assays for Lyme disease and gout and an assay to inform decisions regarding biologic therapies. Research and development expenses include direct costs and an allocation of indirect costs, including amortization, depreciation, rent, supplies, insurance, and repairs and maintenance.
Restructuring, Impairment, and Other Activities Disclosure [Text Block]	Restructuring Charges
	For restructuring plans meeting all of the applicable criteria of ASC 420, Exit or Disposal Cost Obligations, one time termination benefits will be recognized if no future service is required of former employees. Costs associated with the termination of contracts before the end of their term, where costs will continue to be incurred without economic benefit to the entity, will be recognized as liabilities and initially measured at fair value on the date the contract is terminated or when the Company is no longer using the rights conveyed under the contract. Liabilities for other costs associated with restructuring plans will be recognized in the period they were incurred (generally upon receipt of the goods or services). Restructuring charges will be included in the appropriate operating expense category in the Company’s consolidated statements of operations.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based compensation
	The Company accounts for share-based compensation arrangements with employees, officers and directors by recognizing compensation expense based on the grant date fair value of share-based transactions in the consolidated financial statements.
	Share-based compensation for options is based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for share options and recognized as expense on a straight-line basis over the requisite service period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility, expected term and forfeiture rates. The expected volatility rates are estimated based on the actual volatility of comparable public companies over a historical period equal in length to the expected term. The expected terms represent the average time that options are expected to be outstanding based on the midpoint between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not paid dividends and does not anticipate paying cash dividends in the foreseeable future and, accordingly, uses an expected dividend yield of zero. The risk-free interest rate is based on the rate of U.S. Treasury securities with maturities consistent with the estimated expected term of the awards.
	Beginning in 2014, certain employees have been granted restricted shares. There were no issuances of restricted shares in 2013 or 2012. The fair value of restricted shares is calculated based on the closing sale price of the Company’s ordinary shares on the date of issuance. No restricted shares have vested.
	The cumulative expense recognized for share-based transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit for a period represents the movement in cumulative expense recognized as of the beginning and end of that period. No expense is recognized for awards that do not ultimately vest.
	Where the terms of an equity award are modified, the minimum expense recognized is the expense as if the terms had not been modified if the original terms of the award are met. An additional expense is recognized for any modification that increases the total fair value of the share-based compensation, or is otherwise beneficial to the employee as measured at the date of modification.
	Where a share-based compensation award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not yet recognized for the award is recognized immediately. However, if a new award is substituted for the cancelled award, and designated as a replacement award on the date it is granted, the cancelled and new awards are treated as if they were a modification of the original award, as described in the previous paragraph.
	Upon exercise, share options are redeemed for newly issued ordinary shares.
Income Tax, Policy [Policy Text Block]	Income taxes
	The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and its financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized.
	The Company adheres to the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken, or expected to be taken, in a tax return. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not that the Company would be required to pay such additional taxes. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. The Company does not have any accrued interest or penalties associated with any unrecognized tax positions for the years ended December 31, 2014 and 2013.
Ordinary Share Warrant [Policy Text Block]	Ordinary share warrant policy
	Warrants to purchase the Company’s ordinary shares are classified as equity unless otherwise required. Warrants issued with a down round provision, whereby the exercise price would be adjusted downward in the event that additional ordinary shares of the Company or securities exercisable, convertible or exchangeable for the Company’s ordinary shares are issued at a price less than the exercise price, are recorded as a liability and marked to market each reporting period until they are exercised, expire or are otherwise extinguished. Changes in the liability during each reporting period are recorded in other income (expense). The Company has not issued warrants since its IPO in November 2013.
Earnings Per Share, Policy [Policy Text Block]	Basic and diluted net loss per ordinary share
	Earnings or net loss attributable to ordinary shareholders for the period, after deduction of preferred ordinary share preferences, are allocated between the ordinary shareholders and preferred ordinary shareholders based on their respective rights to receive dividends. Basic and diluted net loss per ordinary share is determined by dividing net loss applicable to ordinary shareholders by the weighted-average number of ordinary shares outstanding during the period. As the Company reports net losses, outstanding share options, warrants and preferred ordinary shares, have not been included in the calculation of diluted net loss attributable to ordinary shareholders per share because to do so would be anti-dilutive. Accordingly, the numerator and the denominator used in computing both basic and diluted net loss per share for each period are the same. Since the Company’s participating preferred ordinary shares were not contractually required to share in the Company’s losses, in applying the two-class method to compute basic net loss per share, no allocation was made to preferred ordinary shares if a net loss existed. Prior period share and per share amounts have been adjusted to reflect the reverse share split.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent accounting pronouncements
	In May 2014, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update, or ASU, 2014-09, Revenue from Contracts with Customers, or ASU 2014-09 which converges the FASB and the International Accounting Standards Board standard on revenue recognition. Under ASU 2014-09, a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. This guidance will be effective for the Company for annual and interim periods beginning after December 15, 2016. Early adoption is not permitted. The guidance allows for either “full retrospective” adoption, meaning the standard is applied to all of the periods presented, or “modified retrospective” adoption, meaning the standard is applied only to the most current period presented in the financial statements. The Company is currently evaluating ASU 2014-09 and has not yet determined how it may impact the Company’s financial position or results of operations and related disclosures.
	In August 2014, the FASB issued ASU 2014-15, Presentation of Financial Statements - Going Concern, or ASU 2014-15. ASU 2014-15 will be effective for fiscal years and interim periods beginning after December 15, 2016 and early application is permitted. ASU 2014-15 requires that management evaluate at each annual and interim reporting period whether there is a substantial doubt about an entity’s ability to continue as a going concern within one year of the date that the financial statements are issued. The Company does not expect that the application of ASU 2014-15 will have an impact on the presentation of its results of operations, financial position or disclosures.
	In November 2014, the FASB issued ASU 2014-16, Derivatives and Hedging, or ASU 2014-16. The objective of ASU 2014-16 is to eliminate the existing diversity in practice in accounting for hybrid financial instruments issued in the form of a share. A hybrid financial instrument consists of a “host contract” into which one or more derivative terms have been embedded. ASU 2014-16 requires an entity to consider the terms and features of the entire financial instrument, including the embedded derivative features, in order to determine whether the nature of the host contract is more akin to debt or to equity. ASU 2014-16 is effective for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. A reporting entity should apply ASU 2014-16 using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the annual period of adoption. Retrospective application is permitted to all relevant prior periods. The Company does not expect that the application of ASU 2014-16 will have an impact on the presentation of its results of operations, financial position or disclosures.
	In November 2014, the FASB issued ASU 2014-17, Business Combinations, or ASU 2014-17. ASU 2014-17 provides guidance that allows all acquired entities to choose to apply pushdown accounting in their separate financial statements when an acquirer obtains control of them. The new guidance is effective immediately. The Company does not expect that the application of ASU 2014-17 will have an impact on the presentation of its results of operations, financial position or disclosures.
	In January 2015, the FASB issued ASU 2015-01, Income Statement—Extraordinary and Unusual Items, or ASU 2015-01. ASU 2015-01 eliminates from GAAP the concept of extraordinary items. However, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring. The amendments in ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. The Company does not expect that the application of ASU 2015-01 will have an impact on the presentation of its results of operations, financial position or disclosures.

Note_2_Fair_Value_Measurement_

Note 2 - Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]					Fair value measurements at December 31, 2014 using
	(in thousands)	December 31,			Quoted prices in		Significant		Significant
		2014			active markets		other		unobservable
					for		observable		inputs
					identical assets		inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Contingent purchase price consideration	$	1,218		$	—	$	—	$	1,218
	Total	$	1,218		$	—	$	—	$	1,218
					Fair value measurements at December 31, 2013 using
	(in thousands)	December 31,			Quoted prices in		Significant		Significant
		2013			active markets		other		unobservable
					for		observable		inputs
					identical assets		inputs		(Level 3)
					(Level 1)		(Level 2)
	Liabilities:
	Ordinary share warrants	$	296		$	—	$	—	$	296
	Total	$	296		$	—	$	—	$	296
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	(in thousands)	2014
	Balance – beginning	$	296
	Change in fair value of warrant liability		22
	Reclassification of liability to additional paid-in capital upon exercise of warrants		(318	)
	Contingent purchase price consideration		1,247
	Change in fair value of contingent purchase price consideration		72
	Foreign currency adjustment		(101	)
	Balance – ending	$	1,218
	(in thousands)	2013
	Balance – beginning	$	—
	Initial fair value of warrants at issuance in May 2013		17
	Change in fair value of warrant liability		279
	Reclassification of liability to additional paid-in capital upon exercise of warrants		—
	Balance – ending	$	296

Note_3_Accounts_Receivable_Tab

Note 3 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2014
Receivables [Abstract]
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]		December 31,
	(in thousands)	2014			2013
	Accounts receivable	$	6,937		$	4,919
	Less allowance for uncollectible accounts receivable		(114	)		(165	)
	Accounts receivable, net	$	6,823		$	4,754
Allowance for Credit Losses on Financing Receivables [Table Text Block]		December 31,
	(in thousands)	2014			2013			2012
	Balance at beginning of period	$	(165	)	$	(144	)	$	(200	)
	Provision for bad debt expense		—			(124	)		—
	Write-off, net of recoveries		51			103			56
	Balance at end of period	$	(114	)	$	(165	)	$	(144	)

Note_4_Inventory_Tables

Note 4 - Inventory (Tables)	12 Months Ended
	Dec. 31, 2014
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]		December 31,
	(in thousands)	2014		2013
	Raw materials	$	3,605	$	2,866
	Finished goods		2,820		2,584
	Inventory, net	$	6,425	$	5,450

Note_5_Property_and_Equipment_1

Note 5 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2014
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]		December 31,
	(in thousands)	2014			2013
	Laboratory equipment	$	2,815		$	2,072
	Leasehold improvements		2,869			2,029
	Office equipment, furniture and fixtures		2,603			2,025
	Software		1,065			692
	Specialized shipping containers		1,088			294
	Property and equipment		10,440			7,112
	Less accumulated depreciation		(5,903	)		(4,148	)
	Property and equipment, net	$	4,537		$	2,964

Note_6_Intangible_Assets_Table

Note 6 - Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure Text Block [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]		December 31,
	(in thousands)	2014			2013
	Gross carrying value	$	828		$	878
	Accumulated amortization		(555	)		(547	)
	Other intangible assets, net	$	273		$	331
Schedule of Goodwill [Table Text Block]	Goodwill from Boulder acquisition	$	55
	Foreign currency adjustment		(5	)
	Balance at end of period	$	50

Note_7_Accrued_Liabilities_Tab

Note 7 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities [Table Text Block]		December 31,
	(in thousands)	2014		2013
	Employee related expenses	$	3,348	$	2,766
	Royalties		2,458		2,064
	Professional services		323		99
	Rent		196		366
	Inventory		88		293
	Accrued initial public offering costs		—		845
	Other accrued liabilities		657		503
	Total accrued liabilities	$	7,070	$	6,936

Note_8_Borrowings_Tables

Note 8 - Borrowings (Tables)	12 Months Ended
	Dec. 31, 2014
Debt Disclosure [Abstract]
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
		Fair value		Valuation technique	Assumption	Input
		at date				range/
		of grant				value
	Warrant liability ($ in thousands)	$	3	Black-Scholes	Expected volatility		37.6	%
				option pricing model
					Estimated fair value of ordinary share	$	0.14
					Exercise price	$	0.01
					Expected term (in years)	3
					Dividend yield		0	%
					Risk-free interest rate		0.37	%
		Fair value		Valuation technique	Assumption	Input
		at December 31,				range/
		2013				value
	Warrant liability ($ in thousands)	$	296	Black-Scholes option	Expected volatility		48.6	%
				pricing model
					Estimated fair value of ordinary share	$	19.38
					Exercise price	$	0.8
					Expected term (in years)	9.4
					Dividend yield		0	%
					Risk-free interest rate		2.64	%

Note_9_Share_Capital_Tables

Note 9 - Share Capital (Tables)	12 Months Ended
	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Schedule of Stock by Class [Table Text Block]		Preferred		Preferred ordinary
		ordinary		shares issued
		shares		and outstanding
		authorized
	A preferred ordinary		134,708		134,706
	B preferred ordinary		53,992		53,992
	D preferred ordinary		520,275		487,222
	E preferred ordinary		4,772,557		2,547,496
	F preferred ordinary		2,982,848		2,574,575
	G preferred ordinary		3,728,560		1,503,330
			12,192,940		7,301,321

Note_10_Share_Option_and_Equit1

Note 10 - Share Option and Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]			2014				2013			2012
	Expected dividend yield (%)			—				—			—
	Expected volatility (%)			46.87				47.78			49.43
	Risk-free interest rate (%)			1.86				1.38			1.03
	Expected life of option (years)			6.19				6.22			6.25
	Weighted-average share price ($)			19.66				5.86			0.6
	Weighted-average exercise price ($)			19.66				4.97			0.6
	Model used		Black-Scholes Model				Black-Scholes Model			Black-Scholes Model
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]			Number of ordinary shares				WAEP in $
	Outstanding as of January 1, 2013			1,446,807			$	0.36
	Granted			312,198				5.12
	Exercised			(201,459	)			0.12
	Forfeited			(198,532	)			0.24
	Outstanding as of December 31, 2013			1,359,014				1.5
	Exercisable as of December 31, 2013			1,320,922			$	1.48
	Outstanding as of January 1, 2014			1,359,014			$	1.5
	Granted			633,823				19.66
	Exercised			(65,054	)			0.22
	Forfeited			(50,641	)			12.3
	Outstanding as of December 31, 2014			1,877,142				7.39
	Vested or expected to vest as of December 31, 2014			1,829,020			$	7.27
	Exercisable as of December 31, 2014			914,704			$	2.55
Nonvested Restricted Stock Shares Activity [Table Text Block]			Number of ordinary shares				WAFV in $
	Unvested balance as of January 1, 2014			-			$	-
	Granted			275,500				22.25
	Cancelled			-				-
	Vested			-				-
	Unvested balance as of December 31, 2014			275,500				22.25
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]						Total options outstanding						Total options exercisable
	Exercise prices					Number of options			Weighted-average			Number of options		Weighted-average
									remaining life in					remaining life in
									years					years
	$0.00	-	$1.00				1,153,736						814,055
	$1.01	-	$5.00				42,049						7,901
	$10.00	-	$15.00				160,721						-
	$15.01	-	$20.00				159,262						24,258
	$20.01	-	$25.00				361,374						68,490
							1,877,142			7.9			914,704		6.9
Schedule of Nonvested Share Activity [Table Text Block]			Number of shares				Weighted-average grant
							date fair value
	Balance as of December 31, 2013			761,840			$	1.43
	Granted			633,823				9.32
	Vested			(385,042	)			2.66
	Forfeited			(48,182	)			6.06
	Balance as of December 31, 2014			962,439				5.92
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	(in thousands)		2014				2013			2012
	Cost of revenue		$	330			$	5		$	2
	Research and development			87				1			4
	Sales and marketing			949				26			18
	General and administrative			1,155				108			55
	Total share-based compensation		$	2,521			$	140		$	79

Note_11_Net_Loss_Per_Share_Tab

Note 11 - Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2014
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]			Year ended December 31,
	($ in thousands)		2014				2013				2012
	Numerator:
	Net loss attributable to ordinary shareholders		$	(22,174	)		$	(8,664	)		$	(14,883	)
	Denominator:
	Weighted-average ordinary shares outstanding-basic			17,310,148				3,830,837				1,763,728
	Dilutive effect of ordinary share equivalents resulting from ordinary share options, ordinary share warrants and preferred ordinary shares (as converted)			—				—				—
	Weighted-average ordinary shares outstanding-diluted			17,310,148				3,830,837				1,763,728
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]		Year ended December 31,
		2014				2013				2012
	Options to purchase ordinary shares		1,194,612				1,252,790				1,129,657
	Ordinary share warrant		—				19,473				3,682
	Preferred ordinary shares (as converted)		—				—				7,301,371
	Unvested restricted shares		275,500				—				—

Note_13_Income_Taxes_Tables

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	(in thousands)	2014			2013			2012
	Domestic (United Kingdom)	$	(158	)	$	4,915		$	(2,754	)
	Foreign (United States)		(21,862	)		(13,487	)		(12,280	)
	Loss before income taxes	$	(22,020	)	$	(8,572	)	$	(15,034	)
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	(in thousands)	2014			2013			2012
	Current:
	Federal	$	—		$	—		$	—
	UK		—			—			(173	)
	Japan		119			47			—
	State		35			45			22
	Total current provision		154			92			(151	)
	Deferred:
	Federal		—			—			—
	UK		—			—			—
	State		—			—			—
	Total deferred benefit		—			—			—
		$	154		$	92		$	(151	)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]		2014			2013			2012
	Income tax rate		21.5	%		23.3	%		20	%
	U.K. research and development credit		1.7			—			1.1
	Other		(1.2	)		(0.6	)		(0.3	)
	Effect of foreign tax rate differential		17.9			16.9			15.9
	Valuation allowance		(40.6	)		(40.6	)		(35.7	)
	Effective income tax rate		(0.7	)%		(1.0	)%		1	%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	(in thousands)	2014			2013
	Deferred tax assets:
	Long term deferred tax assets:
	U.S. federal net operating losses	$	24,136		$	16,897
	State net operating loss (net of federal)		3,001			1,659
	U.S. federal research and development credit		110			—
	U.K. net operating loss		7,800			7,408
	Share options		567			112
	Accrued liabilities		97			233
	Other		78			127
	Short term deferred tax assets:
	Accrued liabilities		—			373
	Other assets		—			9
	Total deferred tax assets		35,789			26,818
	Valuation allowance		(35,361	)		(26,413	)
	Total deferred tax assets	$	428		$	405
	Deferred tax liabilities:
	Long term deferred tax liabilities:
	Other assets	$	(428	)	$	(405	)
	Total deferred tax liabilities	$	(428	)	$	(405	)
Summary of Valuation Allowance [Table Text Block]	(in thousands)	2014			2013			2012
	Beginning of year (January 1)	$	26,413		$	22,929		$	17,556
	Increase in valuation allowance		8,948			3,484			5,373
	End of year (December 31)	$	35,361		$	26,413		$	22,929

Note_16_Commitments_and_Contin1

Note 16 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(in thousands)	December 31,
		2014
	Year 1	$	975
	Year 2		982
	Year 3		843
	Year 4		776
	Year 5		261
	Thereafter		—
	Total minimum lease payments	$	3,837
Schedule of Future Minimum Payments for License Agreements [Table Text Block]	(in thousands)	License agreements		Supplier purchase obligations		Total
	Year 1	$	1,688	$	3,180	$	4,868
	Year 2		1,688		250		1,938
	Year 3		1,688		250		1,938
	Year 4		1,688		250		1,938
	Year 5		1,676		—		1,676
	Thereafter		25		—		25
	Total minimum license payments	$	8,453	$	3,930	$	12,383

Note_17_Geographic_Revenue_and1

Note 17 - Geographic Revenue and Long-Lived Assets Distribution (Tables)	12 Months Ended
	Dec. 31, 2014
Segment Reporting [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]		Revenue						Long-lived assets
		Year ended December 31,						Year ended December 31,
	(in thousands)	2014		2013		2012		2014		2013
	United States	$	22,537	$	17,345	$	10,366	$	3,198	$	2,496
	United Kingdom		2,971		2,795		2,466		928		360
	Europe & ROW (excluding United Kingdom)		4,248		4,362		4,064		259		—
	Europe & ROW		7,219		7,157		6,530		1,187		360
	Asia		19,749		14,282		3,789		152		108
	Total	$	49,505	$	38,784	$	20,685	$	4,537	$	2,964

Note_18_Acquisition_Activity_T

Note 18 - Acquisition Activity (Tables)	12 Months Ended
	Dec. 31, 2014
Business Combinations [Abstract]
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	Cash consideration	$	1,724
	Estimated fair value of contingent consideration		1,247
	Total consideration transferred	$	2,971
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Assets acquired:
	Cash	$	8
	Accounts receivable		15
	Inventory		40
	Prepaid expenses and other		12
	Property and equipment		359
	In-process research and development		2,627
	Total assets acquired		3,061
	Liabilities assumed:
	Accounts payable		(97	)
	Accrued liabilities		(14	)
	Other current liabilities		(34	)
	Total liabilities assumed		(145	)
	Net assets acquired		2,916
	Add: goodwill		55
	Total consideration transferred	$	2,971
Business Acquisition, Pro Forma Information [Table Text Block]		Year Ended December 31,
	(in thousands, except share and per share data)	2014			2013
	Total revenues	$	49,577		$	38,923
	Net loss	$	(22,399	)	$	(9,669	)
	Net loss per share—basic and diluted	$	(1.29	)	$	(2.52	)
	Weighted average shares outstanding—basic and diluted		17,310,148			3,830,837

Note_19_Restructuring_Tables

Note 19 - Restructuring (Tables)	12 Months Ended
	Dec. 31, 2014
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs [Table Text Block]	(in thousands)	Abandonment of Excess Facilities			Relocation Costs			Severance			Total
	Balance at December 31, 2013	$	—		$	—		$	—		$	—
	Costs incurred in 2014		86			70			16			172
	Payments		(44	)		(42	)		(16	)		(102	)
	Balance at December 31, 2014	$	42		$	28		$	—		$	70

Note_1_Description_of_Business1

Note 1 - Description of Business and Significant Accounting Policies (Details)

0 Months Ended

12 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

0 Months Ended

12 Months Ended

12 Months Ended

Nov. 21, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Nov. 21, 2013

Nov. 20, 2013

Oct. 30, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Jul. 31, 2014

Nov. 21, 2013

Nov. 21, 2013

Oct. 30, 2013

Nov. 21, 2013

Nov. 21, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2014

Dec. 31, 2013

USD ($)

USD ($)

USD ($)

USD ($)

GBP (£)

GBP (£)

USD ($)

USD ($)

USD ($)

Lab Equipment Office Equipment Furniture And Fixtures [Member]

Lab Equipment Office Equipment Furniture And Fixtures [Member]

Software Development [Member]

Specialized Shipping Containers [Member]

Milestone Payments [Member]

Fosun Note [Member]

Fosun Note [Member]

Fosun Note [Member]

Fosun Note [Member]

Reverse Stock Split [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Restricted Stock [Member]

Pledged As Secuirty For Operating Lease [Member]

Pledged As Secuirty For Operating Lease [Member]

Pledged as Collateral for Procurement Cards [Member]

Shanghai Fosun Long March Medical Science Co Ltd [Member]

Riken Genesis Co., Ltd. [Member]

Other Costs Incurred [Member]

Maximum [Member]

Minimum [Member]

Boulder Diagnostics, Inc. [Member]

Embedded Derivative Financial Instruments [Member]

USD ($)

USD ($)

Pledged as Collateral for Procurement Cards [Member]

Pledged as Collateral for Procurement Cards [Member]

USD ($)

USD ($)

USD ($)

Sales Revenue, Net [Member]

Sales Revenue, Net [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Customer Concentration Risk [Member]

Customer Concentration Risk [Member]

Note 1 - Description of Business and Significant Accounting Policies (Details) [Line Items]

Stockholders' Equity Note, Stock Split, Conversion Ratio

6.705

Common Stock, Par or Stated Value Per Share (in Dollars per share)

£ 0.006705

£ 0.006705

$0.01

$0.00

Stock Issued During Period, Shares, New Issues (in Shares)

6,164,000

Shares Issued, Price Per Share (in Dollars per share)

$12

$12

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)

804,000

65,054

201,459

9,378

Proceeds from Issuance Initial Public Offering

$63,900,000

Payments of Stock Issuance Costs

10,100,000

General and Administrative Expense

14,837,000

12,119,000

8,068,000

1,900,000

Number of Operating Segments

1

Number of Major Customers

2

Concentration Risk, Percentage

17.00%

14.00%

Convertible Notes Payable

5,000,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Conversion, Converted Instrument, Amount

50,000

50,000

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

467,551

Discount to the IPO Offering Price

10.00%

10.00%

Derivative, Loss on Derivative

561,000

561,000

561,000

Restricted Cash and Cash Equivalents

100,000

100,000

312,000

399,000

80,000

Property, Plant and Equipment, Useful Life

10 years

3 years

3 years

3 years

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

6,100,000

Finite-Lived Intangible Asset, Useful Life

10 years

5 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

0.00%

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (in Shares)

0

Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued

$0

$0

Note_2_Fair_Value_Measurement_1

Note 2 - Fair Value Measurement (Details) (USD $)	1 Months Ended
	Apr. 30, 2014	Dec. 31, 2013	31-May-13	Jul. 31, 2014
Note 2 - Fair Value Measurement (Details) [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			15,791
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$0.80
Derivative Liability, Noncurrent		$296,000
Ordinary Share Warrants [Member]
Note 2 - Fair Value Measurement (Details) [Line Items]
Stock Issued During Period, Shares, Warrant Exercised (in Shares)	15,148
Ordinary Share Warrants [Member]
Note 2 - Fair Value Measurement (Details) [Line Items]
Derivative Liability, Noncurrent	318,000	296,000
Milestone Payments [Member] | Boulder Diagnostics, Inc. [Member]
Note 2 - Fair Value Measurement (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				6,100,000
Loan Agreement with Commercial Bank [Member] | Revolving Credit Facility [Member]
Note 2 - Fair Value Measurement (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			5,000,000
Loan Agreement with Commercial Bank [Member]
Note 2 - Fair Value Measurement (Details) [Line Items]
Debt Instrument, Face Amount			6,000,000
Debt Instrument, Additional Borrowing Amount If Certain Revenue Milestones Are Met			1,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			15,791
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$0.80
Revolving Credit Facility [Member]
Note 2 - Fair Value Measurement (Details) [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$5,000,000

Note_2_Fair_Value_Measurement_2

Note 2 - Fair Value Measurement (Details) - Liabilities Measured at Fair Value on Recurring Basis (USD $)	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2014
Note 2 - Fair Value Measurement (Details) - Liabilities Measured at Fair Value on Recurring Basis [Line Items]
Contingent purchase price consideration	$1,218,000
Liabilities measured at fair value	1,218,000	296,000
Ordinary share warrants		296,000
Ordinary Share Warrants [Member] | Fair Value, Inputs, Level 3 [Member]
Note 2 - Fair Value Measurement (Details) - Liabilities Measured at Fair Value on Recurring Basis [Line Items]
Ordinary share warrants		296,000
Ordinary Share Warrants [Member]
Note 2 - Fair Value Measurement (Details) - Liabilities Measured at Fair Value on Recurring Basis [Line Items]
Ordinary share warrants		296,000	318,000
Fair Value, Inputs, Level 3 [Member]
Note 2 - Fair Value Measurement (Details) - Liabilities Measured at Fair Value on Recurring Basis [Line Items]
Contingent purchase price consideration	1,218,000
Liabilities measured at fair value	$1,218,000	$296,000

Note_2_Fair_Value_Measurement_3

Note 2 - Fair Value Measurement (Details) - Changes in the Fair Value of the Company's Level 3 Financial Liabilities (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$296
Foreign currency adjustment	-101
Balance	1,218
Ordinary Share Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Initial fair value of warrants at issuance in May 2013		17
Change in fair value	22	279
Reclassification of liability to additional paid-in capital upon exercise of warrants	-318
Contingent Purchase Price Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Change in fair value	72
Contingent purchase price consideration	$1,247

Note_3_Accounts_Receivable_Det

Note 3 - Accounts Receivable (Details) - Accounts Receivable, Net (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts Receivable, Net [Abstract]
Accounts receivable	$6,937	$4,919
Less allowance for uncollectible accounts receivable	-114	-165
Accounts receivable, net	$6,823	$4,754

Note_3_Accounts_Receivable_Det1

Note 3 - Accounts Receivable (Details) - Allowance for Uncollectible Accounts Receivable (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Allowance for Uncollectible Accounts Receivable [Abstract]
Balance at beginning of period	($165)	($144)	($200)
Provision for bad debt expense		-124
Write-off, net of recoveries	51	103	56
Balance at end of period	($114)	($165)	($144)

Note_4_Inventory_Details_Inven

Note 4 - Inventory (Details) - Inventory (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory [Abstract]
Raw materials	$3,605	$2,866
Finished goods	2,820	2,584
Inventory, net	$6,425	$5,450

Note_5_Property_and_Equipment_2

Note 5 - Property and Equipment, Net (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 5 - Property and Equipment, Net (Details) [Line Items]
Depreciation (in Dollars)	$1.80	$1	$0.70
Property and Equipment Excluding Software and Specialized Shipping Containers [Member] | Minimum [Member]
Note 5 - Property and Equipment, Net (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Property and Equipment Excluding Software and Specialized Shipping Containers [Member] | Maximum [Member]
Note 5 - Property and Equipment, Net (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Software and Software Development Costs [Member]
Note 5 - Property and Equipment, Net (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Specialized Shipping Containers [Member]
Note 5 - Property and Equipment, Net (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years

Note_5_Property_and_Equipment_3

Note 5 - Property and Equipment, Net (Details) - Property and Equipment, Net (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]
Property and equipment	$10,440	$7,112
Less accumulated depreciation	-5,903	-4,148
Property and equipment, net	4,537	2,964
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,815	2,072
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,869	2,029
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	2,603	2,025
Software and Software Development Costs [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	1,065	692
Specialized Shipping Containers [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$1,088	$294

Note_6_Intangible_Assets_Detai

Note 6 - Intangible Assets (Details) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jul. 31, 2014
Note 6 - Intangible Assets (Details) [Line Items]
Amortization of Intangible Assets	$43,000	$43,000	$30,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	41,000
Finite-Lived Intangible Assets, Amortization Expense, Year Two	41,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three	41,000
Finite-Lived Intangible Assets, Amortization Expense, Year Four	26,000
Finite-Lived Intangible Assets, Amortization Expense, Year Five	25,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets				2,627,000
Goodwill, Acquired During Period	55,000
IPR&D [Member] | Boulder Diagnostics, Inc. [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets				2,600,000
Licensing Agreements [Member] | Minimum [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Licensing Agreements [Member] | Maximum [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	9 years
Licensing Agreements [Member] | Weighted Average [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	8 years 109 days
Licensing Agreements [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Increase (Decrease) in Intangible Assets, Current			100,000
Patents [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Increase (Decrease) in Intangible Assets, Current		200,000
Boulder Diagnostics, Inc. [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Goodwill, Acquired During Period				$55,000
Minimum [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	5 years
Maximum [Member]
Note 6 - Intangible Assets (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	10 years

Note_6_Intangible_Assets_Detai1

Note 6 - Intangible Assets (Details) - Intangible Assets (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Intangible Assets [Abstract]
Gross carrying value	$828	$878
Accumulated amortization	-555	-547
Other intangible assets, net	$273	$331

Note_6_Intangible_Assets_Detai2

Note 6 - Intangible Assets (Details) - Changes in Carrying Amount of Goodwill (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Jul. 31, 2014
Changes in Carrying Amount of Goodwill [Abstract]
Goodwill from Boulder acquisition	$55
Foreign currency adjustment	-5
Balance at end of period	$50	$55

Note_7_Accrued_Liabilities_Det

Note 7 - Accrued Liabilities (Details) - Accrued Liabilities (USD $)	Dec. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accrued Liabilities [Abstract]
Employee related expenses	$3,348	$2,766
Royalties	2,458	2,064
Professional services	323	99
Rent	196	366
Inventory	88	293
Accrued initial public offering costs		845
Other accrued liabilities	657	503
Total accrued liabilities	$7,070	$6,936

Note_8_Borrowings_Details

Note 8 - Borrowings (Details) (USD $)

1 Months Ended

2 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

Mar. 31, 2012

Apr. 30, 2012

Feb. 29, 2012

Apr. 30, 2012

Jun. 30, 2012

Dec. 31, 2013

31-May-13

Nov. 21, 2013

Oct. 30, 2013

Mar. 31, 2014

Dec. 31, 2014

Jun. 30, 2013

Apr. 30, 2014

Dec. 31, 2012

Note 8 - Borrowings (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

15,791

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

0.8

Cost to Build Facility, Percentage

80.00%

Loans Payable, Current

$170,000

$137,000

Loans Payable, Noncurrent

563,000

454,000

Shares Issued, Price Per Share (in Dollars per share)

$12

$12

Series F Preferred Stock [Member] | Tranche 1 [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

137,922

Series F Preferred Stock [Member] | Tranche 2 [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

45,974

Series F Preferred Stock [Member] | Automatically Convertible Uponthe Consummationofa Non Qualifying Equity Fundraising [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$10.88

Percentage of F Preferred Units Issued to Nominal Amount of Outstanding Notes

65.00%

Series F Preferred Stock [Member] | Atthe Optionofthe Holder [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$10.88

Percentage of F Preferred Units Issued to Nominal Amount of Outstanding Notes

65.00%

Series F Preferred Stock [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Conversion of Stock, Amount Issued

2,000,000

Debt Instrument, Unamortized Discount

1,300,000

Tranche 1 [Member] | Common Stock [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

45,973

Tranche 2 [Member] | Common Stock [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

15,324

Atthe Optionofthe Holder [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Conversion of Stock, Shares Converted (in Shares)

350,923

Automatic Conversion [Member] | Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Unamortized Discount

100,000

Lease Incentive [Member]

Note 8 - Borrowings (Details) [Line Items]

Loans Payable, Current

108,000

Loans Payable, Noncurrent

358,000

Fractional Shares [Member] | Convertible Debt [Member] | Tranche 1 [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

0

Common Stock [Member]

Note 8 - Borrowings (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

15,148

Debt Conversion, Converted Instrument, Amount

5,049,000

Shares Issued, Price Per Share (in Dollars per share)

$12

Pledged as Collateral for Procurement Cards [Member] | Maximum [Member]

Note 8 - Borrowings (Details) [Line Items]

Restricted Cash and Cash Equivalents

100,000

100,000

Pledged as Collateral for Procurement Cards [Member]

Note 8 - Borrowings (Details) [Line Items]

Restricted Cash and Cash Equivalents

80,000

Convertible Debt [Member] | Tranche 1 [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Proceeds from Notes Payable

3,000,000

Convertible Debt [Member] | Tranche 2 [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Proceeds from Notes Payable

1,000,000

Convertible Debt [Member] | Atthe Optionofthe Holder [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Convertible, Beneficial Conversion Feature

0

Convertible Debt [Member] | The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Face Amount

4,000,000

Debt Instrument, Interest Rate, Stated Percentage

10.00%

Percentage of F Preferred Units Issued to Nominal Amount of Tranches

50.00%

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

$1.62

Additional Borrowing [Member] | Loan Agreement with Commercial Bank [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Face Amount

1,000,000

Loan Agreement with Commercial Bank [Member] | Revolving Credit Facility [Member]

Note 8 - Borrowings (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

5,000,000

Loan Agreement with Commercial Bank [Member] | Prime Rate [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

2.75%

Loan Agreement with Commercial Bank [Member] | Minimum [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

6.00%

Loan Agreement with Commercial Bank [Member]

Note 8 - Borrowings (Details) [Line Items]

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

15,791

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

0.8

Derivative Liability, Fair Value, Gross Liability

296,000

Debt Instrument, Face Amount

6,000,000

Debt Instrument, Unamortized Discount

17,000

Debt Issuance Cost

142,000

Class of Warrant or Right, Outstanding (in Shares)

15,791

Fosun Note [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Interest Rate, Stated Percentage

8.00%

Debt Conversion, Converted Instrument, Shares Issued (in Shares)

467,551

Conversion of Stock, Shares Converted (in Shares)

467,551

467,551

Convertible Notes Payable

5,000,000

Discount to the IPO Offering Price

10.00%

10.00%

Debt Conversion, Converted Instrument, Amount

50,000

50,000

Derivative, Loss on Derivative

561,000

561,000

Secured Debt [Member] | Prime Rate [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

1.50%

Secured Debt [Member] | London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Basis Spread on Variable Rate

2.50%

Secured Debt [Member]

Note 8 - Borrowings (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

3,000,000

Long-term Line of Credit

1,500,000

1,500,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

3,682

3,682

Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)

$0.07

Derivative Liability, Fair Value, Gross Liability

3,000

296,000

Proceeds from Warrant Exercises

257.74

The 2012 Notes [Member]

Note 8 - Borrowings (Details) [Line Items]

Debt Instrument, Face Amount

4,000,000

4,000,000

Revolving Credit Facility [Member]

Note 8 - Borrowings (Details) [Line Items]

Line of Credit Facility, Maximum Borrowing Capacity

5,000,000

Marlborough Massachusetts [Member]

Note 8 - Borrowings (Details) [Line Items]

Area of Real Estate Property (in Square Feet)

14,500

Incentive from Lessor

581,640

Note_8_Borrowings_Details_Summ

Note 8 - Borrowings (Details) - Summary of Warrants (Secured Debt [Member], USD $)	1 Months Ended	12 Months Ended
	Feb. 29, 2012	Dec. 31, 2013
Class of Warrant or Right [Line Items]
Fair value (in Dollars)	$3,000	$296,000
Valuation technique	Black-Scholes option pricing model	Black-Scholes option pricing model
Input range/value	37.60%	48.60%
Input range/value (in Dollars per share)	$0.14	$19.38
Input range/value	3 years	9 years 146 days
Input range/value	0.00%	0.00%
Input range/value	0.37%	2.64%
Ordinary Shares [Member]
Class of Warrant or Right [Line Items]
Input range/value (in Dollars per share)	$0.01	$0.80

Note_9_Share_Capital_Details

Note 9 - Share Capital (Details)

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Nov. 21, 2013

Feb. 28, 2011

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2012

Nov. 21, 2013

Oct. 30, 2013

Apr. 30, 2012

Mar. 31, 2012

Feb. 28, 2011

Dec. 31, 2014

Jun. 30, 2012

Jun. 30, 2012

Jan. 04, 2013

Dec. 31, 2012

Jun. 30, 2012

Dec. 31, 2014

Oct. 31, 2007

Aug. 31, 2008

Aug. 31, 2008

Jun. 30, 2012

Nov. 21, 2013

Apr. 30, 2012

Mar. 31, 2012

Feb. 28, 2011

Dec. 31, 2012

Dec. 31, 2014

Nov. 21, 2013

Dec. 31, 2014

Apr. 30, 2012

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

Series F Preferred Stock [Member]

Series F Preferred Stock [Member]

Series F Preferred Stock [Member]

Series F Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series G Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Series E Preferred Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Restricted Stock [Member]

The 2012 Notes [Member]

USD ($)

Tranche 1 [Member]

Payment of Interest [Member]

Tranche 2 [Member]

Tranche 2 [Member]

USD ($)

USD ($)

Tranche 1 [Member]

Tranche 2 [Member]

Cashless Exerciseof Warrants Issuein October 2007 [Member]

Issuedto E Preferred Shareholdersasa Resultof Anti Dilution Rights [Member]

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

USD ($)

GBP (£)

Note 9 - Share Capital (Details) [Line Items]

Common Stock, Shares, Outstanding

17,614,650

17,255,267

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

1,877,142

1,359,014

1,446,807

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

275,500

Stock Issued During Period, Shares, New Issues

6,164,000

45,974

137,922

919,498

1,495,464

7,882

966,417

817,761

6,164,000

15,324

45,973

306,499

Stock Issued During Period, Value, New Issues (in Dollars)

$10,000,000

$11,000,000

$8,100,000

$17,000,000

$9,000

Debt Instrument, Face Amount (in Dollars)

4,000,000

Minimum Percentage of Consent of E, F, and G Preferred Ordinary Shareholders to Approve Certain Corporate Actions

60.00%

Maximum Amount of Debt Creation Allowed Without Shareholder Consent (in Dollars) (in Dollars)

2,000,000

Convertible Preferred Stock, Conversion Ratio

1.5

1.25

1

Preferred Stock, Liquidation Preference Per Share

$8.15

$11.40

$17.54

$17.54

£ 0.006705

Maximum Percentage of Value of Assets or Sale Amount Available as Liquidation Preferrence

50.00%

Preferred Stock, Liquidation Preference to Original Issue Price

8.153

8.153

Shares Issued, Price Per Share (in Dollars per share)

$12

$12

$12

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

804,000

65,054

201,459

9,378

Proceeds from Issuance Initial Public Offering (in Dollars)

$63,900,000

Common Stock, Shares Authorized

40,103,528

25,189,285

Common Stock, Shares, Issued

17,614,650

17,255,267

Note_9_Share_Capital_Details_P

Note 9 - Share Capital (Details) - Preferred Ordinary Shares	Dec. 31, 2012
Class of Stock [Line Items]
Preferred ordinary shares authorized	12,192,940
Preferred ordinary shares issued and outstanding	7,301,321
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred ordinary shares authorized	134,708
Preferred ordinary shares issued and outstanding	134,706
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred ordinary shares authorized	53,992
Preferred ordinary shares issued and outstanding	53,992
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred ordinary shares authorized	520,275
Preferred ordinary shares issued and outstanding	487,222
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred ordinary shares authorized	4,772,557
Preferred ordinary shares issued and outstanding	2,547,496
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred ordinary shares authorized	2,982,848
Preferred ordinary shares issued and outstanding	2,574,575
Series G Preferred Stock [Member]
Class of Stock [Line Items]
Preferred ordinary shares authorized	3,728,560
Preferred ordinary shares issued and outstanding	1,503,330

Note_10_Share_Option_and_Equit2

Note 10 - Share Option and Equity Incentive Plans (Details) (USD $)	0 Months Ended	12 Months Ended
	Nov. 21, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Nov. 30, 2013
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		4 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)		$9.32	$3.04	$0.27
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Rate		5.00%	5.00%	5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$15,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value		10,800,000	24,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares)	804,000	65,054	201,459	9,378
Proceeds from Stock Options Exercised		14,000	24,000	1,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value		900,000	3,900,000	6,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		1,000,000	42,000	12,000
Allocated Share-based Compensation Expense		2,521,000	140,000	79,000
Employee Stock Option [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		4,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		2 years 6 months
Allocated Share-based Compensation Expense		1,600,000
Restricted Stock [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized		4,900,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		3 years 73 days
Allocated Share-based Compensation Expense		$900,000
Until Second Aniversaryof Vesting Start Dateof Employee First Option [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		0.00%
Second Anniversary of Grant Date [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		40.00%
Third Anniversary of Grant Date [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		30.00%
Fourth Anniversary of Grant Date [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage		30.00%
The 2013 Plan [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in Shares)					2,684,563
Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase, Percentage of Shares Outstanding					4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)		1,589,956

Note_10_Share_Option_and_Equit3

Note 10 - Share Option and Equity Incentive Plans (Details) - Valuation Assumptions, Stock Options (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Valuation Assumptions, Stock Options [Abstract]
Expected volatility (%)	46.87%	47.78%	49.43%
Risk-free interest rate (%)	1.86%	1.38%	1.03%
Expected life of option (years)	6 years 69 days	6 years 80 days	6 years 3 months
Weighted-average share price ($)	$19.66	$5.86	$0.60
Weighted-average exercise price ($)	$19.66	$4.97	$0.60
Model used	Black-Scholes Model	Black-Scholes Model	Black-Scholes Model

Note_10_Share_Option_and_Equit4

Note 10 - Share Option and Equity Incentive Plans (Details) - Stock Options Activity (USD $)	0 Months Ended	12 Months Ended
	Nov. 21, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock Options Activity [Abstract]
Number of ordinary shares, beginning of period		1,359,014	1,446,807
WAEP in $, end of period		$1.50	$0.36
Number of ordinary shares, beginning of period		1,877,142	1,359,014	1,446,807
WAEP in $, end of period		$7.39	$1.50	$0.36
Vested or expected to vest as of December 31, 2014		1,829,020
Vested or expected to vest as of December 31, 2014		$7.27
Number of ordinary shares, exercisable		914,704	1,320,922
WAEP in $, exercisable		$2.55	$1.48
Number of ordinary shares, granted		633,823	312,198
WAEP in $, granted		$19.66	$4.97	$0.60
Number of ordinary shares, exercised	-804,000	-65,054	-201,459	-9,378
WAEP in $, exercised		$0.22	$0.12
Number of ordinary shares, forfeited		-50,641	-198,532
WAEP in $, forfeited		$12.30	$0.24

Note_10_Share_Option_and_Equit5

Note 10 - Share Option and Equity Incentive Plans (Details) - Activity of Restricted Shares (Restricted Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Restricted Stock [Member]
Note 10 - Share Option and Equity Incentive Plans (Details) - Activity of Restricted Shares [Line Items]
Number of ordinary shares	275,500
WAFV in $	$22.25
Granted	275,500
Granted	$22.25

Note_10_Share_Option_and_Equit6

Note 10 - Share Option and Equity Incentive Plans (Details) - Summary of Options Outstanding and Exercisable (USD $)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of options outstanding	1,877,142
Weighted-average remaining life in years, outstanding	7 years 328 days
Number of options exercisable	914,704
Weighted-average remaining life in years, exercisable	6 years 328 days
Price Range 1 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower exercise price (in Dollars per share)	0
Upper exercise price (in Dollars per share)	1
Number of options outstanding	1,153,736
Number of options exercisable	814,055
Price Range 2 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower exercise price (in Dollars per share)	1.01
Upper exercise price (in Dollars per share)	5
Number of options outstanding	42,049
Number of options exercisable	7,901
Price Range 3 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower exercise price (in Dollars per share)	10
Upper exercise price (in Dollars per share)	15
Number of options outstanding	160,721
Price Range 4 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower exercise price (in Dollars per share)	15.01
Upper exercise price (in Dollars per share)	20
Number of options outstanding	159,262
Number of options exercisable	24,258
Price Range 5 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Lower exercise price (in Dollars per share)	20.01
Upper exercise price (in Dollars per share)	25
Number of options outstanding	361,374
Number of options exercisable	68,490

Note_10_Share_Option_and_Equit7

Note 10 - Share Option and Equity Incentive Plans (Details) - Activity of Unvested Share Option (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Activity of Unvested Share Option [Abstract]
Number of shares	962,439	761,840
Weighted-average grant date fair value	$5.92	$1.43
Granted	633,823	312,198
Granted	$9.32	$3.04	$0.27
Vested	-385,042
Vested	$2.66
Forfeited	-48,182
Forfeited	$6.06

Note_10_Share_Option_and_Equit8

Note 10 - Share Option and Equity Incentive Plans (Details) - Expense Recognized During the Year Related to Share-based Compensation Transactions (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	$2,521	$140	$79
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	330	5	2
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	87	1	4
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	949	26	18
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation	$1,155	$108	$55

Note_11_Net_Loss_Per_Share_Det

Note 11 - Net Loss Per Share (Details) - Reconciliation of the Numerator and Denominator Used in Computing Basic and Diluted Net Loss Per Share (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net loss attributable to ordinary shareholders (in Dollars)	($22,174)	($8,664)	($14,883)
Denominator:
Weighted-average ordinary shares outstanding-basic	17,310,148	3,830,837	1,763,728
Weighted-average ordinary shares outstanding-diluted	17,310,148	3,830,837	1,763,728

Note_11_Net_Loss_Per_Share_Det1

Note 11 - Net Loss Per Share (Details) - Antidilutive Securities	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	1,194,612	1,252,790	1,129,657
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities		19,473	3,682
Convertible Preferred Ordinary Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities			7,301,371
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities	275,500

Note_12_Related_Party_Transact1

Note 12 - Related Party Transactions (Details) (USD $)	12 Months Ended		0 Months Ended	1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Nov. 21, 2013	Oct. 30, 2013
Note 12 - Related Party Transactions (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)			$12	$12
Shanghai Fosun Long March Medical Science Co Ltd [Member]
Note 12 - Related Party Transactions (Details) [Line Items]
Revenue from Related Parties	$8,500,000	$1,300,000
Accounts Receivable, Related Parties	1,400,000
Fosun Note [Member]
Note 12 - Related Party Transactions (Details) [Line Items]
Convertible Notes Payable				5,000,000
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Debt Conversion, Converted Instrument, Amount			50,000	50,000
Conversion of Stock, Shares Converted (in Shares)			467,551	467,551
Discount to the IPO Offering Price			10.00%	10.00%
Derivative, Loss on Derivative			$561,000	$561,000

Note_13_Income_Taxes_Details

Note 13 - Income Taxes (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 13 - Income Taxes (Details) [Line Items]
Effective U.K. Corporate Tax Rate	21.50%	23.30%	20.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%	34.00%
Employee Service Share-based Compensation, Tax Benefit Realized from Exercise of Stock Options	$0.80
State and Local Jurisdiction [Member]
Note 13 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	63.6	45.1
Earliest Tax Year [Member]
Note 13 - Income Taxes (Details) [Line Items]
Open Tax Year	2011
Latest Tax Year [Member]
Note 13 - Income Taxes (Details) [Line Items]
Open Tax Year	2014
Research Tax Credit Carryforward [Member]
Note 13 - Income Taxes (Details) [Line Items]
Income Tax Credits and Adjustments			0.2
Her Majesty's Revenue and Customs (HMRC) [Member]
Note 13 - Income Taxes (Details) [Line Items]
Effective U.K. Corporate Tax Rate	21.50%	23.30%	20.00%
Operating Loss Carryforwards	39	37
Internal Revenue Service (IRS) [Member]
Note 13 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	$71.90	49.7

Note_13_Income_Taxes_Details_C

Note 13 - Income Taxes (Details) - Components of Loss before Income Taxes (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 13 - Income Taxes (Details) - Components of Loss before Income Taxes [Line Items]
Loss before income taxes	($22,020)	($8,572)	($15,034)
Her Majesty's Revenue and Customs (HMRC) [Member]
Note 13 - Income Taxes (Details) - Components of Loss before Income Taxes [Line Items]
Domestic (United Kingdom)	-158	4,915	-2,754
Internal Revenue Service (IRS) [Member]
Note 13 - Income Taxes (Details) - Components of Loss before Income Taxes [Line Items]
Foreign (United States)	($21,862)	($13,487)	($12,280)

Note_13_Income_Taxes_Details_C1

Note 13 - Income Taxes (Details) - Components for the Income Tax Expense (Benefit) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Current:
State	$35	$45	$22
Total current provision	154	92	-151
	154	92	-151
Her Majesty's Revenue and Customs (HMRC) [Member]
Current:
Current foreign tax			-173
National Tax Agency, Japan [Member]
Current:
Current foreign tax	$119	$47

Note_13_Income_Taxes_Details_E

Note 13 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 13 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation [Line Items]
Income tax rate	21.50%	23.30%	20.00%
Her Majesty's Revenue and Customs (HMRC) [Member]
Note 13 - Income Taxes (Details) - Effective Income Tax Rate Reconciliation [Line Items]
Income tax rate	21.50%	23.30%	20.00%
U.K. research and development credit	1.70%		1.10%
Other	-1.20%	-0.60%	-0.30%
Effect of foreign tax rate differential	17.90%	16.90%	15.90%
Valuation allowance	-40.60%	-40.60%	-35.70%
Effective income tax rate	-0.70%	-1.00%	1.00%

Note_13_Income_Taxes_Details_D

Note 13 - Income Taxes (Details) - Deferred Tax Assets (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Long term deferred tax assets:
Share options	$567	$112
Total deferred tax assets	35,789	26,818
Valuation allowance	-35,361	-26,413	-22,929	-17,556
Total deferred tax assets	428	405
Other assets	-428	-405
Total deferred tax liabilities	-428	-405
State and Local Jurisdiction [Member]
Long term deferred tax assets:
State net operating loss (net of federal)	3,001	1,659
Long Term Deferred Tax Assets [Member]
Long term deferred tax assets:
Accrued liabilities	97	233
Other	78	127
Short Term Deferred Tax Assets [Member]
Long term deferred tax assets:
Accrued liabilities		373
Other		9
Internal Revenue Service (IRS) [Member]
Long term deferred tax assets:
U.S. federal net operating losses	24,136	16,897
U.S. federal research and development credit	110
Her Majesty's Revenue and Customs (HMRC) [Member]
Long term deferred tax assets:
U.K. net operating loss	$7,800	$7,408

Note_13_Income_Taxes_Details_R

Note 13 - Income Taxes (Details) - Rollforward of the Company's Valuation Allowance (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Rollforward of the Company's Valuation Allowance [Abstract]
Beginning of year (January 1)	$26,413	$22,929	$17,556
Increase in valuation allowance	8,948	3,484	5,373
End of year (December 31)	$35,361	$26,413	$22,929

Note_14_Intellectual_Property_1

Note 14 - Intellectual Property - License Agreements (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
License Agreements Tex Block [Abstract]
Number of License Agreements	3
Royalty Expense	$4.80	$3.70	$2.40
License Costs	$0.10	$0.30	$0.10
Aggregate Royalty Rate, Percent of Gross Product and Service Revenue	10.00%	10.00%	11.00%

Note_15_Employee_Benefit_Plans1

Note 15 - Employee Benefit Plans (Details) (The UK Plan [Member], USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
The UK Plan [Member]
Note 15 - Employee Benefit Plans (Details) [Line Items]
Defined Contribution Plan, Minimum Annual Contributions Per Employee, Percent	5.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	5.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$0.50	$0.40	$0.40

Note_16_Commitments_and_Contin2

Note 16 - Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Number of Non-Cancelable Operating Leases	4
Operating Leases, Rent Expense	$0.70	$0.70	$0.70

Note_16_Commitments_and_Contin3

Note 16 - Commitments and Contingencies (Details) - Future Minimum Lease Payments under the Non-Cancelable Operating Leases (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future Minimum Lease Payments under the Non-Cancelable Operating Leases [Abstract]
Year 1	$975
Year 2	982
Year 3	843
Year 4	776
Year 5	261
Thereafter	0
Total minimum lease payments	$3,837

Note_16_Commitments_and_Contin4

Note 16 - Commitments and Contingencies (Details) - Future Minimum Payments Required under the License Agreements (USD $)	Dec. 31, 2014
In Thousands, unless otherwise specified
Future Minimum Payments Required under the License Agreements [Abstract]
Year 1	$1,688
Year 1	3,180
Year 1	4,868
Year 2	1,688
Year 2	250
Year 2	1,938
Year 3	1,688
Year 3	250
Year 3	1,938
Year 4	1,688
Year 4	250
Year 4	1,938
Year 5	1,676
Year 5	0
Year 5	1,676
Thereafter	25
Thereafter	0
Thereafter	25
Total minimum license payments	8,453
Total minimum license payments	3,930
Total minimum license payments	$12,383

Note_17_Geographic_Revenue_and2

Note 17 - Geographic Revenue and Long-Lived Assets Distribution (Details)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 17 - Geographic Revenue and Long-Lived Assets Distribution (Details) [Line Items]
Number of Geographies where the Company Operated in	3
Sales Revenue, Net [Member] | Geographic Concentration Risk [Member] | Asia [Member]
Note 17 - Geographic Revenue and Long-Lived Assets Distribution (Details) [Line Items]
Concentration Risk, Percentage	43.00%	44.00%	82.00%
Sales Revenue, Net [Member] | Geographic Concentration Risk, Asia [Member] | JAPAN
Note 17 - Geographic Revenue and Long-Lived Assets Distribution (Details) [Line Items]
Concentration Risk, Percentage	54.00%	55.00%	7.00%

Note_17_Geographic_Revenue_and3

Note 17 - Geographic Revenue and Long-Lived Assets Distribution (Details) - Revenue and Long-Lived Assets (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$49,505,000	$38,784,000	$20,685,000
Long-lived assets	4,537,000	2,964,000
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	22,537,000	17,345,000	10,366,000
Long-lived assets	3,198,000	2,496,000
UNITED KINGDOM
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	2,971,000	2,795,000	2,466,000
Long-lived assets	928,000	360,000
Europe And ROW Excluding UK [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	4,248,000	4,362,000	4,064,000
Long-lived assets	259,000
European Union [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	7,219,000	7,157,000	6,530,000
Long-lived assets	1,187,000	360,000
Asia [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	19,749,000	14,282,000	3,789,000
Long-lived assets	$152,000	$108,000

Note_18_Acquisition_Activity_D

Note 18 - Acquisition Activity (Details) (USD $)	1 Months Ended			3 Months Ended	12 Months Ended
	Jul. 31, 2014	Feb. 28, 2013	Jan. 31, 2013	Sep. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Note 18 - Acquisition Activity (Details) [Line Items]
Escrow Deposit							$300,000
Proceeds from Other Deposits			300,000
Reimbursement Expense		300,000
Payments to Acquire Businesses, Net of Cash Acquired					1,716,000
Business Combination, Consideration Transferred, Liabilities Incurred	1,247,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	2,627,000
Goodwill and Intangible Asset Impairment				0
Revenues					49,505,000	38,784,000	20,685,000
Operating Income (Loss)					-21,861,000	-7,351,000	-12,931,000
Other Income [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination Breakup Fee		200,000
General and Administrative Expense [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Acquisition Related Costs				181,000
In Process Research and Development [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Fair Value Inputs, Discount Rate	15.00%
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	2,600,000
Lyme Disease Assay [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	1,800,000
Biologics for Autoimmune Disease Assay [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	500,000
Gout Assay [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets	300,000
Milestone Payments [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	6,100,000
Milestone Payments for Completion of Studies Related to Aquired Technologies [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	400,000
Milestone Payments for Development of Diagnostic Test Kits [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	700,000
Milestone Payments for the First Patient Enrolled in an Institutional Review Board Approved Study [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	500,000
Milestone Payments for Issuance of Patents [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	1,500,000
Milestone Payments for Approvals or Clearances by the FDA [Member] | Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	3,000,000
Boulder Diagnostics, Inc. [Member]
Note 18 - Acquisition Activity (Details) [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired	1,700,000
Business Combination, Consideration Transferred, Liabilities Incurred	1,200,000
Revenues					42,000
Operating Income (Loss)					($396,000)

Note_18_Acquisition_Activity_D1

Note 18 - Acquisition Activity (Details) - Business Acquisition (USD $)	1 Months Ended
In Thousands, unless otherwise specified	Jul. 31, 2014
Business Acquisition [Abstract]
Cash consideration	$1,724
Estimated fair value of contingent consideration	1,247
Total consideration transferred	$2,971

Note_18_Acquisition_Activity_D2

Note 18 - Acquisition Activity (Details) - Assets Acquired and Liabilities Assumed (USD $)	Dec. 31, 2014	Jul. 31, 2014
In Thousands, unless otherwise specified
Assets Acquired and Liabilities Assumed [Abstract]
Cash		$8
Accounts receivable		15
Inventory		40
Prepaid expenses and other		12
Property and equipment		359
In-process research and development		2,627
Total assets acquired		3,061
Accounts payable		-97
Accrued liabilities		-14
Other current liabilities		-34
Total liabilities assumed		-145
Net assets acquired		2,916
Add: goodwill	50	55
Total consideration transferred		$2,971

Note_18_Acquisition_Activity_D3

Note 18 - Acquisition Activity (Details) - Pro Forma Information (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Pro Forma Information [Abstract]
Total revenues	$49,577	$38,923
Net loss	($22,399)	($9,669)
Net loss per share—basic and diluted (in Dollars per share)	($1.29)	($2.52)
Weighted average shares outstanding—basic and diluted (in Shares)	17,310,148	3,830,837	1,763,728

Note_19_Restructuring_Details

Note 19 - Restructuring (Details) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2014	Dec. 31, 2014
Note 19 - Restructuring (Details) [Line Items]
Restructuring Charges	$172,000
Research and Development Expense [Member]
Note 19 - Restructuring (Details) [Line Items]
Restructuring Charges		182,000
Boulder Diagnostics, Inc. [Member]
Note 19 - Restructuring (Details) [Line Items]
Restructuring and Related Cost, Number of Positions Eliminated		4
Write-off Abandoned Equipment [Member]
Note 19 - Restructuring (Details) [Line Items]
Restructuring Charges		$10,000

Note_19_Restructuring_Details_

Note 19 - Restructuring (Details) - Accrued Restructuring Costs (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$70,000	$0
Costs incurred in 2014	172,000
Payments	-102,000
Facility Closing [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	42,000	0
Costs incurred in 2014	86,000
Payments	-44,000
Employee Relocation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	28,000	0
Costs incurred in 2014	70,000
Payments	-42,000
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve		0
Costs incurred in 2014	16,000
Payments	($16,000)

Note_20_Subsequent_Events_Deta

Note 20 - Subsequent Events (Details) (USD $)	0 Months Ended	12 Months Ended		0 Months Ended
In Millions, except Share data, unless otherwise specified	Nov. 21, 2013	Dec. 31, 2014	Dec. 31, 2013	Jan. 29, 2015	Jan. 30, 2015	Jan. 15, 2015	Oct. 30, 2013
Note 20 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	6,164,000
Shares Issued, Price Per Share (in Dollars per share)	$12						$12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		633,823	312,198
Private Placement [Member] | Subsequent Event [Member]
Note 20 - Subsequent Events (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				4,255,319
Shares Issued, Price Per Share (in Dollars per share)				$11.75
Subsequent Event [Member] | Underwriters [Member]
Note 20 - Subsequent Events (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)				$11.04
Subsequent Event [Member]
Note 20 - Subsequent Events (Details) [Line Items]
Time Period for Underwriters to Excercise Share Grants from Date of Prospectus				30 days
Additional Shares Granted to Underwritten in Private Placement				638,297
Proceeds from Issuance of Private Placement, Gross (in Dollars)					$57.50
Proceeds from Issuance of Private Placement (in Dollars)					$53.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						355,509